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ABSTRACT 
Sweden is a low burden country for tuberculosis (TB). New cases occur mainly among 
immigrants from countries with a higher TB prevalence. Most persons infected with TB (latent 
TB) will not develop disease (active TB). Prolonged treatment is necessary and can cause 
severe adverse drug reactions. A well-functioning TB program is essential to interrupt the 
transmission of infection in the community. The increasing global problem of resistant TB-
strains necessitates development of a new tuberculosis vaccine that is more effective than the 
Bacillus Calmette Guerin (BCG) vaccination that has long been in use.  
Globally, human immunodeficiency virus (HIV) is the single strongest medical risk factor for 
active TB. The implementation of anti-retroviral treatment (ART) in 1996 completely changed 
the prognosis for persons living with HIV. By restituting the immune defense, ART has 
provided a strong protective effect against active TB. ART in combination with anti-TB 
treatment entails a higher risk of adverse drug reactions and this risk is even greater if ART is 
introduced during TB treatment. Sweden is a low burden country for HIV and more than 90% 
of all HIV-infected individuals in Sweden receive effective ART.  
In paper I we described the socio-demographic and clinical characteristics of the 127 HIV-
infected persons that developed active TB in Stockholm County 1987–2013. The majority of 
the patients in the co-infected cohort were foreign-born (87%). After the introduction of ART 
in 1996 the success of TB treatment increased from 65% to 91%. In patients diagnosed with 
co-infection after 1996, treatment success was predicted by ART treatment (odds ratio (OR) 
13.3, 95% conﬁdence interval (CI) 1.5–114.8) and a CD4⁺ cell count at TB diagnosis >200 
cells/μl (OR 17.2, 95% CI 1.2–236.6). Adverse reactions severe enough to lead to modiﬁcation 
of anti-TB treatment occurred in 23% of the patients diagnosed with co-infection after 1996, 
and the risk of adverse events was significantly increased if ART was introduced after TB 
diagnosis (OR 13.3, 95% CI 1.6–112.4).  
BCG, the TB vaccine used since the 1920s, is most effective against active disease in children 
but does not give adequate protection in adults. In paper II we performed a phase 1 study, 
investigating the safety and the immunogenicity of the new vaccine candidate H4:IC31, 
consisting of a fusion protein of two TB antigens (Ag85B and TB10.4) and an adjuvant (IC31). 
In two randomized and double-blinded studies, conducted in Sweden and Finland, including 
BCG-vaccinated healthy individuals, 125 study subjects were immunized twice with different 
doses of antigen and adjuvant or placebo. The vaccine was well tolerated with only mild to 
moderate, mainly self-limiting adverse events: injection-site pain, myalgia, arthralgia, fever 
and post-vaccination inflammatory reaction at the site of screening tuberculin skin test 
injection. The vaccine triggered an antigen-specific and multifunctional CD4⁺ cell response 
and cytokine production, most prominent after two doses of 5, 15 or 50 µg of H4 combined 
with 500 µg of IC31.  
Latent TB infection (LTBI) is defined as a detectable immune response against TB without 
signs or symptoms of active disease. Treatment for LTBI is recommended by the Public Health 
Agency of Sweden to prevent active TB in persons with untreated HIV-infection. In contrast, 
the National Reference Group for Antiretroviral therapy in Sweden (RAV) recommends 
neither screening nor treatment for LTBI in this group, with reference to Sweden’s well-
functioning HIV care; almost all HIV-infected persons are offered ART and if they 
nevertheless develop active TB the close follow-up of this group is considered sufficient for 
early detection and initiation of TB treatment. In paper III we studied the incidence of and risk 
factors for active TB in persons living with HIV in Stockholm County, 1996–2016. We 
observed an overall incidence rate of active TB of 6.2 cases (95% CI 5.1–7.6) per 1 000 person-
years with a significant decline over the study period. Originating from a TB-endemic region 
was the only characteristic associated with a higher risk of active TB (Hazard Ratio (HR) 8.84 
(95% CI 3.09–23.61). The number of patients needed to treat for LTBI to prevent one case of 
active TB among patients from TB-endemic regions was 22 (95% CI 26–47). Although the 
incidence of TB declined significantly during the study period, it was still 80 times higher than 
in the general population at the end of the study.  
Recurrence of infection after completed antibiotic treatment is reported to occur in around 2% 
of TB patients, in low-endemic settings. Recurrence can be caused by relapse of infection or 
reinfection by another TB strain. Molecular typing with whole genome sequencing (WGS) can 
distinguish relapse from reinfection with a high resolution. As an evaluation of current 
treatment strategies and treatment control, study IV was aimed to analyze the frequency of TB 
recurrence in Stockholm County, 1996–2016. Recurrence was defined as a new TB infection 
more than 180 days after successful treatment completion. The recurrence frequency was 0.7% 
in 2,552 patients diagnosed with culture-verified TB. With WGS analysis, 71% were classified 
as relapse cases. Drug-resistant TB was present in 50% of the patients with relapse. No acquired 
drug resistance was detected with WGS comparing the isolates in relapse cases.  
In conclusion, several interventions are needed to further reduce the incidence rate of TB in 
Sweden. The introduction of ART in 1996 has dramatically enhanced the success rate of TB 
treatment in patients co-infected with HIV and TB (Paper I). Since the introduction of ART, 
the incidence of active TB in persons living with HIV in Stockholm County has also declined 
significantly. However, our data indicate that the addition of screening and treatment of LTBI 
in persons with HIV could be expected to further decrease the incidence of TB in persons from 
TB-endemic regions (Paper III). Stockholm has a low TB relapse frequency, indicating a well-
functioning TB care. Relapse occurs mainly among patients with resistant TB, which should 
be considered in the follow-up of these patients (Paper IV). The new vaccine candidate 
H4:IC31 is safe and immunogenic. Encouraging results from a phase 2 study of the vaccine 
candidate performed in South Africa were presented in 2018 (Paper II).  
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1 BACKGROUND 
In 2014 the World Health Organization (WHO) set a goal to reduce the global tuberculosis 
(TB) incidence with 90%, by 2035 (1). The major means to achieve this goal include preventive 
treatment of people with high risk of disease, early TB diagnosis and treatment of all people 
with TB, and collaborative care for people with human immunodeficiency virus (HIV) and TB 
(1). In TB low-endemic settings (<100/100.000 inhabitants) such as Sweden, a majority of TB 
cases result from progression of latent TB infection (LTBI) rather than from local transmission 
(2). Efforts should be concentrated on the prevention of disease in vulnerable groups with high 
risk of progression from LTBI to active disease: migrants from TB-endemic settings; people 
with recent infection (especially children aged <5 years); and people with impaired immunity 
(e.g. owing to HIV infection or immunosuppressive treatments); but also through Bacillus 
Calmette-Guerin (BCG)-vaccination of infants at risk for TB (2). 
TB is a contagious disease, caused by the bacillus Mycobacterium tuberculosis (M.tb) (3). The 
disease has been a curse since the beginning of human history with a high mortality rate but 
also with social implications and stigma (4). Crowding, poverty and malnourishment have 
always been associated with TB. Socioeconomic development and welfare can reduce the 
incidence of disease (5). With the intention to prevent TB infection, the BCG-vaccine was 
developed by Calmette and Guerin in the 1920s (4). The degree of efficacy of the vaccine is 
not well characterized, but it provides a strong protection against miliary and meningeal TB in 
infants (6). The vaccine was widely used in Europe from the 1940s and it contributed to the 
reduction of the epidemic, but improved economy, welfare and the segregation of infectious 
cases in sanatoria probably explain most of the decline in TB incidence before the 
implementation of active medical treatment in 1950s (4, 7). In areas with access to proper 
treatment, the incidence of TB continued to fall until the 1990s, when the spread of HIV fueled 
the epidemic (8).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 2 
1.1 EPIDEMIOLOGY 
In 2019, TB remains a major cause of morbidity and mortality globally. In 2017, 10 million 
people were diagnosed with TB and 1.6 million died from the disease worldwide, according to 
the WHO (9). Figure 1. A major driver of the disease is HIV-co-infection and multi-drug 
resistant TB (MDR-TB) (9, 10). TB is a global concern: although primarily affecting high-
incidence settings in Asia and Africa, with globalization and migrating populations it also 
reaches low-endemic countries (9, 11, 12). During recent years (2013–2017) the incidence of 
TB has been falling by an average of 2% per year globally and in Europe and the African region 
by 4-5% per year (9).  
Figure 1. Global incidence of tuberculosis 2017 
 
1.1.1 Tuberculosis and HIV 
In 2017, 9% of all cases of active TB in the world occurred in persons living with HIV (a 
majority in sub-Saharan Africa) and TB was the major cause of mortality, with 300,000 deaths, 
in dually infected individuals (9). Figure 2. With increasing access to antiretroviral treatment 
(ART) against HIV in combination with better access to both HIV and TB diagnosis and 
treatment, the number of deaths among people living with HIV has fallen by 20% from 2015–
2017 but still in 2017 the global access to ART was only 40% (9). The risk for TB activation 
and disease has been shown to be strongly reduced by early start of ART after HIV diagnosis 
(13). 
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Figure 2. Prevalence of HIV in tuberculosis cases 2017 
 
1.1.2 Drug-resistant tuberculosis 
Resistant TB is an increasing problem, with the highest burden in India, China and the Russian 
Federation (9). The degree of resistance ranges from mono-drug resistance to first line drugs 
(most commonly isoniazid (INH) and rifampicin (RIF) resistance), to MDR-TB (M.tb strains 
resistant to both INH and RIF), to extensively drug-resistant TB (XDR-TB) (MDR-TB plus 
resistance to fluoroquinolones and at least one injectable second-line drug) and they are all a 
major threat (14). In 2016 >18% of new cases in the Russian Federation were infected with a 
RIF-resistant or MDR-TB strain (15). Also in Sweden we observe a growing proportion of 
patients with MDR-TB, although still around 3% (16).  
1.1.3 Tuberculosis in Sweden  
In the beginning of the 20th century Sweden was a high-burden country for TB, with over 300 
cases per 100,000 inhabitants. After the end of World War II the incidence fell dramatically 
with improved socio-economic welfare and fell even more after effective medical treatment 
became accessible (16). Sweden has been a low-burden country since the 1950s. Figure 3. 
With increasing immigration from TB-endemic regions (>100/100,000 inhabitants) the last 
twenty years, foreign-born patients represent >90% of all cases and 1996–2016 the median 
incidence was 6.0 cases per 100,000 population and year (16). Figure 4. Patients with TB are 
concentrated to the large cities with one third in Stockholm (16). TB is a notifiable disease in 
Sweden and it is mandatory to report TB-cases in the National Reporting System and Registry 
for Communicable Diseases (SmiNet), according to the Communicable Disease Act (16). The 
Public Health Agency of Sweden is responsible for surveying the disease and for storage of 
clinical strains.  
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Figure 3. Incidence of tuberculosis in Sweden 1940–2018. (The Public Health Agency of 
Sweden) 
 
 
Figure 4. Number of tuberculosis cases in Sweden 1989–2017. Persons born in Sweden in 
dark color and persons born abroad in light color. (The Public Health Agency of Sweden)
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1.2 TUBERCULOSIS PATHOGENESIS 
1.2.1 The pathogen 
M.tb is a rod-shaped, slow-growing, aerobic and facultative intracellular bacteria. The 
mycobacterial envelope is thick and lipid-rich, consisting of long-chain mycolic acids, causing 
its acid fast property when microbiologically stained (17). The M.tb complex consists of M.tb, 
M africanum, M bovis, M microti and M caprae. TB-disease is usually caused by M.tb in 
humans. M bovis infection in humans can occur in contact with cattle or after BCG-vaccination 
or after BCG urine bladder instillation. The other members of the M.tb complex rarely cause 
disease in humans (18). 
1.2.2 Transmission 
The bacilli are spread by aerosols formed when an infected individual coughs, sneezes or sings. 
The aerosol contains droplets with one to three bacilli each. The droplets are small enough that 
when inhaled by another person, they reach the alveoli and can there establish infection (19). 
In an immunocompetent individual, immunity is usually established within 3 to 8 weeks after 
infection. The bacilli are then retained in a dormant stage, so-called latent tuberculosis infection 
(LTBI) (20). Endogenous reactivation of dormant M.tb in persons with LTBI (secondary or 
post-primary TB) occurs in 5-10% of infected individuals during their lifetime and usually 
happens within 2 years after the initial infection (20). In a person whose immune response does 
not control the primary infection, primary progressive TB develops. (21). If the new host 
develops pulmonary TB and M.tb can be detected in sputum, the circle of transmission is 
closed. Extrapulmonary disease is not contagious. 
1.2.3 Immunity  
In the upper respiratory tract, M.tb is encountered by the innate immune response in the 
respiratory mucosa. Local epithelial cells secrete mucus and antimicrobial peptides in an 
attempt to prevent the microbe from entering the deep airways. If the bacilli manage to 
penetrate this first defense barrier, they are ingested by alveolar macrophages that are the 
primary host cells to be infected with M.tb. Dendritic cells are essential in priming of naïve T 
cell responses, and thus uptake of bacterial products or apoptotic M.tb-infected macrophages 
are instrumental in triggering adaptive immunity. M.tb-infected macrophages and dendritic 
cells carrying M.tb antigens, migrate to regional lymph nodes and from there bacilli spread 
hematogenously further, throughout the body (22). M.tb-specific T cells are also primed in the 
lymph nodes and travel back to the site of infection in the lung to assist macrophages and other 
immune cells to combat the infection. This stage is known as primary TB infection and lasts 
from days to weeks; it is usually asymptomatic (22) but can sometimes cause transient disease 
symptoms, such as fever, erythema nodosum and poly arthritis (23).   
In the macrophages the ingested bacilli are contained in phagosomes, where growth is restricted 
by acidification, reactive oxygen, nitric oxide and antimicrobial peptides (24). The intracellular 
bacteria can be killed by apoptosis of the macrophage (25) and the induction of autophagy (26) 
but complete eradication of M.tb is rare as the bacteria have developed strategies to survive 
these attacks (see below) (27). Infected macrophages secret cytokines; interleukin (IL)-1b, IL-
6, IL-12, IL-18 and tumor necrosis factor-α (TNF-α) which activate dendritic cells and attract 
T cells, natural killer (NK) cells as well as other immune cells subsets that result in enhanced 
local inflammation. Infected macrophages and dendritic cells present M.tb antigens on the 
cell surface via the major histocompatibility complex (MHC) class II. When recognized by 
CD4⁺ cells, differentiation and clonal expansion of T-helper 1 cells (Th1-cells) is induced. Th1 
cells secrete IL-2, interferon-γ (IFN- and TNF-α. TNF-α stimulates autophagy, enhancing 
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intracellular killing of M.tb in the macrophages, but also initates cell migration and adhesion 
of new inflammatory cells and cell destruction within the infected tissue it affects (27).  
Infected macrophages now fuse and start forming multinucleated giant cells or differentiate 
into foam cells. Infected macrophages attract lymphocytes, monocytes and neutrophils that 
surround the infected cells in a structure called a granuloma. The TB granuloma is an important 
hallmark of human TB. During progressive inflammation, apoptotic macrophages release 
bacilli into the center of the granuloma that can liquefy and support extracellular growth of 
M.tb. The center is first permissive of growth but as it becomes acidic and oxygen-depleted, 
M.tb bacilli turn into a dormant stage and only divide occasionally, so-called LTBI (28). 
Cytolytic CD8⁺ T cells (CTLs) also play an important role in the battle against M.tb. CTL cells 
secrete cytolytic (perforin and granzymes) and antimicrobial peptides (granulysin), killing the 
bacteria via granule-mediated cytotoxicity.  However, excessive secretion of extracellular 
peptides leads to necrosis and tissue destruction. The CTL cell activity is downregulated by 
macrophages in the granuloma (29). During this phase antigen-specific long-lived memory T 
cells are formed, so called CD8αα+ T cells, as they express the co-receptors αα (30). Although 
M.tb. is an intracellular pathogen and control of infection mainly dependent on cell-mediated 
immunity, the interest in humoral immunity has increased lately. B-cells have been shown to 
aggregate around granulomas. B cell depletion has been connected with hampered granuloma 
formation. Antibodies against lipoarabinomannan (LAM) and BCG have been shown to 
opsonize M.tb for phagocytosis by macrophages (31). Importantly, B cell can also have a role 
as antigen-presenting cells and may thus be involved in the activation of effector T cells. 
In infants and immunocompromised individuals such as persons living with HIV or with 
impaired function of TNF-α or IFN-γ, granulomas are initially poorly formed and 
unstructured. This results in an early, enhanced dissemination of bacteria into the blood 
stream, a so-called primary progressive TB. If a person with LTBI is later 
immunocompromised, granulomas formed earlier lose their stability. The granuloma grows 
and a soft (caseous) necrotic center is formed. Bacilli can then escape into the bloodstream and 
airways (32).  
M.tb has developed several strategies to survive in the infected individual. This is achieved by 
secreted effector molecules (33). In the mycobacterial genome, the region of difference 1 
(RD1) encodes for the ESX-1 secretion system, producing the early secretory antigen target 6 
(ESAT-6), culture filtrate protein 10 (CFP-10) and TB10.4, but also several other antigens. The 
antigens are secreted by the M.tb inside the macrophage and, by binding to the cell surface, 
help the bacilli translocate from the lysosome into the cytosol, thereby escaping degradation 
(34). The 85-antigen family (Ag85 a-c) has been found to prevent maturation of the lysosomes 
where the bacilli are contained (35). M.tb also uses other virulence mechanisms that promote 
spread to new cells and inhibit host cell apoptosis (32).  
1.2.4 The role of HIV in TB pathogenesis 
It is well known that HIV infection increases the risk of active TB, but also that TB increases 
HIV replication. Therefore, co-infection is advantageous to both pathogens, and has been called 
“the evil couple” or “the cursed duet”. People with untreated HIV are approximately 26 times 
more likely to develop active TB (36). The immune balance is lost as HIV proceeds. HIV 
infection leads to CD4⁺-cell depletion, reducing the body’s defense capabilities. When CD4⁺ 
cells are lacking, neutrophils are recruited in granulomas. Neutrophils induce IL-10 and IFN-α 
production, leading to further suppression of T cell function and M.tb growth (37). HIV also 
increases the numbers of CD8⁺ and CLT cells to control viremia. Unfortunately, these cells are 
dysfunctional because of exhaustion, with a low level cytotoxic peptides and a low TNFα 
production (29). HIV also infects alveolar macrophages, resulting in reduced macrophage 
viability, impaired M.tb-associated apoptosis inhibition of effector functions and accelerated 
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M.tb growth (38). Other parts of the immune system are also impaired by HIV co-infection 
(39), including down-regulation of MHC class II as well as co-stimulatory molecules on HIV-
infected dendritic cells, which impairs priming of antigen-specific T cell responses.  On the 
other hand, HIV entry into CD4⁺ cells and HIV replication are enhanced by M.tb-induced up-
regulation of the HIV co-receptors CXCR4 and CCR5 (important for the entry of HIV virus 
into the CD4⁺ cell) as well as an induced pro-inflammatory cytokine cascade (39-42).  
Patients with HIV and pulmonary TB have fewer necrotic granulomas and less pulmonary 
cavitation and therefore also lower transmissibility of M.tb. This can be explained by the fact 
that T cell responses to M.tb contribute substantially to cellular necrosis and tissue damage and 
with decreasing CD4⁺ cell numbers, these mechanisms are impaired (43).  
Treatment of HIV with ART leads to recovery of the immune system. Early initiation has been 
proven to reduce mortality significantly (44). The numbers of CD4⁺ cells increases and central 
memory cells are redistributed from lymphoid tissues to the periphery. After three months of 
treatment a rise in naïve CD4⁺ cells and gradually also the level of effector cells is noted (45, 
46). The recovering immune system regains its ability to reacts to the M.tb infection. The 
combination of antimycobacterial treatment and ART leads to rapid killing of bacilli. Large 
amounts of microbial components are released. This, in combination with regained and 
dysregulated immune response, can cause a so-called immune reconstitution inflammatory 
syndrome (IRIS). The patient, although actually recovering from both infections, presents with 
new or worsened clinical symptoms (39, 47). IRIS is caused either by worsening of known TB 
disease or unmasking of previously asymptomatic M.tb infection (48). The risk for IRIS is 
higher in patients with an initial low CD4⁺-count and high HIV-viral and bacillary load but also 
with short interval between TB treatment and ART introduction. In TB IRIS, an increased acute 
neutrophilic inflammation has been noted at the site of M.tb infection, before the recovery of 
the CD4⁺ T cells; this inflammation is interpreted as a recovery of the innate immune response 
and failure of immune regulation (49). The patient’s genetic predisposition is probably also of 
importance for the development of IRIS (46). The overall estimated risk for IRIS is 18% with 
a mortality of about 3%, mainly in patients with central nervous system TB (47, 50). IRIS 
reaction has also been noted after discontinuation of TNF antagonist therapy (51).  
If ART is introduced within six months after primary HIV infection, both CD4⁺ and CD8⁺ cells 
normalize. If treatment is delayed, the HIV infection turn into a chronic phase with a continuous 
high level of dysfunctional CD8⁺ cells and the CD4⁺ cells have an impaired IFN-γ production 
(29, 52).  
1.2.5 TB antigens and vaccines 
The BCG vaccine has been shown to induce clonal expansion of CD4⁺ and CD8⁺ cells that 
differentiate into effector memory T cells, migrating to the affected tissues, often the lung. 
Central memory T cells localize in secondary lymphoid organs. The cells can later proliferate 
and differentiate into new effector cells when exposed to M.tb antigen (53).  
The RD1 genome (mentioned above) is missing in the less pathogenic BCG vaccine strains, 
M. bovis and in most environmental mycobacteria (54). In new, recombinant BCG vaccines 
the RD1 genome is reintroduced, rendering a more immunogenic but also a more virulent 
vaccine (55).  
The new subunit or conjugate vaccines containing ESAT-6, CFP-10, TB10.4 and Antigen 85b 
(Ag85b), have been shown to induce IFN- γ secretion and to boost the central and resident 
memory CD8+ T cell and NK cell response achieved by BCG (55). Other interesting M.tb 
antigens used in the subunit vaccine candidate “M72/AS01E” are recombinant Mtb32A and 
Mtb39A (encoded by ppe18/Rv1196 and pepA/Rv0125). These antigens have been shown to 
bind to MHC class I and II epitopes and thereby induce CD4⁺ and CD8⁺ cell responses (56). 
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Other antigens (Rv2660c, Rv1733c, Rv1813c, Rv2628, Rv2029c, and Rv2659c) have been 
shown to be associated with latency and are used in vaccine candidates.  
The immune responses measured in studies of different vaccine candidates, described below, 
are basically CD4⁺ and CD8⁺ cells and their expression of Th1 cytokines IFN- TNF and IL-
2. T-cells that produce a high amount of different cytokines are called multifunctional T-cells 
and have been shown to be crucial in determining protection of conjugate vaccines against a 
wide spectrum of pathogens. Durable immunity, has been shown to be obtained with the 
development of effector memory T-cells from multifunctional T-cells, mainly CD8⁺ cells. 
CD8αα+ T cells has been shown to represent a compartment of long-lived memory T-cells.  
(57, 58). There is at present no immunological correlate between the magnitude of memory T 
cell response and their cytokine co-expression and protection against M.tb (59).  
1.2.6 Drug resistance 
During suboptimal treatment, resistant M.tb strains appear by the selection of pre-existing 
bacteria with random mutations for resistance (60). Drug-resistant TB (DR-TB) is often divided 
into: mono-drug-resistant – resistance to one first-line TB-drug; multi-drug-resistant (MDR)-
TB – resistance to RIF and INH; extensively resistant (XDR)-TB – MDR resistance plus 
resistance to fluoroquinolone and any injectable drug (likely to change as injectables have been 
downgraded in treatment recommendations); and totally drug-resistant (TDR)-TB – resistance 
to a wider range of drugs than XDR-TB (14, 61). 
1.3 TB INFECTION  
TB infection is commonly divided into latent and active disease, but this seems to be a 
simplification. The current proposed paradigm is a dynamic spectrum ranging from full 
immunity to active TB disease (62). Despite the immune defenses described above, the bacilli 
manage to survive and continue replicating in the majority of cases. Active mycobacterial 
replication may eventually decline, leading at least temporarily to subclinical active infection. 
However, if the immune control is lost, for some reason, the bacterial load increases and 
symptoms and overt clinical disease develop (63). This concept is supported by the fact that 
isoniazid (INH), globally the most frequently used drug for the treatment of LTBI, acts by 
inhibiting mycobacterial cell wall synthesis and is therefore only efficacious against actively 
replicating organisms and that persons without clinical symptoms can be temporarily culture-
positive for M.tb in sputum (64). This is also supported by the fact that the same mutation 
frequency (0.2-0.3 single nucleotide polymorphisms per genome per year (see below)) has been 
found in M.tb strains from patients infected decades before active disease as seen in outbreak 
strains (65). Despite these findings, I will in my presentation keep to the conventional latent 
and active TB concept. 
1.4 LATENT TB INFECTION  
LTBI diagnosis is based on immune recognition of TB antigens, as the numbers of bacilli are 
too small for identification. This means that the true prevalence of the disease is unknown and 
the sensitivity and specificity of the commercially available tests cannot be ascertained. The 
diagnosis of active TB is therefore often a surrogate marker of a former LTBI (66). Available 
tests for LTBI cannot differentiate between active disease, remote or recent LTBI or memory 
of previous infection (67). The overall global prevalence of LTBI in 2014 has been estimated 
to 23%, with a mathematical model (68). 
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1.4.1 Diagnosis of LTBI 
Tuberculin skin test (TST): Tuberculin, first invented by Robert Koch, consisted of cultured, 
filtrated and heat-sterilized M.tb (69). It was later precipitated to isolated proteins in a 
standardized procedure, by Florence Seibert in the 1930s, forming the denoted Purified Protein 
Derivative (PPD-S) (70). The currently used PPD RT23 has been produced by Statens Serum 
Institute in Copenhagen since 1958. The dose of PPD is expressed in tuberculin units (TU) 
correlating to 0.02 µg of dry protein substance. The WHO recommends a dose of 2 TU (71). 
With the commonly used Mantoux-method, PPD is injected intradermally on the forearm. If 
the antigens are recognized the innate immune response activates dendritic cells and 
Langerhans cells. Antigenic material is phagocytized and presented to T cells. Secreted IFN-γ, 
TNF-α and IL-1 attracts neutrophils. Cellular infiltration causes a skin induration. This is called 
a delayed-type hypersensitivity (DTH) reaction (72). The transverse diameter of induration is 
measured after 48-72 hours and is expressed in millimeters. TST ≥5 mm is regarded as positive. 
This limit is used in Sweden, for non BCG-vaccinated children and immunocompromised 
patients. The TST reaction can be false positive due to cross-reactivity with non-tuberculosis 
mycobacteria (NTM) and BCG vaccination. Therefore, to improve specificity, the limit for a 
positive test is raised to ≥10 mm in BCG-vaccinated children and non-immunocompromised 
adults (73). The test can remain positive as a sign of retained immunoreactivity after cleared 
infection. This has been shown after completed treatment of active TB and is hypothetically 
transferable to LTBI (74). The test can also be false negative, see below. Other disadvantages 
of the test are the subjective nature of the assessment and measuring of the skin reaction, but 
also that the patient has to attend the clinic twice. Nonetheless, the test is well established and 
used worldwide.  
Interferon gamma release assays (IGRAs): This relatively new technique is an in-vitro assay, 
invented to overcome the problem of cross-reactivity when using TST, described above. The 
M.tb secretory antigens (absent in BCG and most environmental mycobacteria), ESAT-6, CFP-
10 and TB7.7, are presented to T cells. In case of recognition, IFN-γ production is induced and 
measured in the test. Two IGRAs are commercially available. In the QuantiFERON-TB Gold 
Plus (QFT) (Cellestis Limited, Carnegie, Victoria, Australia), whole blood is collected in four 
tubes, one containing ESAT-6, CFP-10 and TB7.7, stimulating CD4⁺ T cells, one with 
unknown antigens stimulating CD4⁺ and CD8⁺ T cells, one positive control containing mitogen 
and one negative control without stimulant. The IFN-γ production is measured using an 
enzyme-linked immunosorbent assay (ELISA) method (75, 76). In the T-SPOT.TB-test an 
enzyme-linked immunospot (ELISPOT) (Oxford Immunotec) method is used to detect 
lymphocyte-derived IFN-γ response to ESAT-6 and CFP-10. There is some evidence that the 
T-SPOT.TB test is more robust than the QFT in immunocompromised persons with low 
lymphocyte count, as a standardized number of cells per assay is used. 
The tests for latent TB can all be false negative due to, for example, viral or bacterial infection 
(HIV, measles, mumps, typhoid fever, etc.), vaccination (other than BCG), disseminated TB, 
chronic renal failure, disease of lymphoid organs and medical immunosuppression (77).  
In a review of 72 earlier studies in high and low TB endemic countries, the pooled sensitivity 
of TST (with 10 mm cut-off) and IGRA to detect LTBI in a non-BCG-vaccinated population 
was equally good (79%) and specificity was high (97%). In a BCG-vaccinated population the 
TST specificity was 59% (78). In a meta-analysis of 38 articles, the positive predictive value 
(PPV), to predict the risk of developing active TB among those with LTBI, were similarly poor 
for both TST and IGRA (TST 1–7% and IGRA 0–13%) (79). The negative predictive value of 
the tests is high (>99%) (80). 
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Flow-cytometric Assay for Specific Cell-mediated Immune-response in Activated whole blood 
assay (FASCIA): In this method whole blood is cultured with specific antigens for seven days. 
Thereafter, the sample is examined with a flow cytometric technique based on the 
differentiation, i.e. size and granularity, of resting and proliferating CD4⁺ cells and their 
cytokine response. The long-term incubation with antigens results in a larger number of 
responding cells than in QFT and T-spot TB test, when the cells are only incubated overnight. 
Mononuclear antibodies can be used for the detection of surface antigens in T cells subsets 
(CD3⁺, CD3⁺CD4⁺, CD3⁺CD8αβ⁺ and CD3⁺ 71 CD8αα⁺ T cells). Antigens used in TB 
diagnosis are Ag85A, 69 Ag85B and TB10.4 (81). 
New diagnostic methods for LTBI: Gene expression analysis or so-called transcriptomics is a 
newly discovered and promising tool using genome analysis to measure RNA expression. 
Whole blood signature reflects changes in immune cell composition and altered gene 
expression for the discrimination of latent and active TB (82).  
1.4.2 Treatment of latent TB  
Screening and treatment for LTBI are important tools to achieve the WHO goals of reducing 
TB incidence (36). Screening for LTBI is recommended by both the Public Health Agency of 
Sweden and the WHO, for persons with high risk for later active TB. This includes newly 
arrived asylum seekers and persons with evidence of TB infection less than two years ago (with 
priority to children <18 years and pregnant women) and persons with untreated HIV infection, 
planned transplant-related immunosuppressive therapy or treatment with TNF-α inhibitors. 
Treatment is recommended to be offered to these groups if they show evidence or suspicion of 
LTBI, when active TB has been ruled out (83). Other factors with a high risk for disease are 
silicosis, chronic renal failure (hemodialysis) and fibronodular scarring of the lungs (83, 84).  
The Public Health Agency of Sweden recommendations for the treatment of LTBI in adults 
(83): 
 INH for 6-9 months, or 
 INH and RIF for 3 months or 
 Rifapentine and high dose INH once weekly for 3 months or 
 RIF for 4 months (in case of known INH resistance)  
These treatments have been shown to be effective and safe in several studies (85). The 
calculation of effectiveness is based on an estimated sensitivity of the test, treatment efficacy 
and adherence to treatment. Adherence to treatment regimens is a problem. In a systematic 
review of studies of LTBI treatment, initiation and completion in the European Union varied 
between 7-86% in migrants but was higher in patients with co-morbidities (75-92%) (86). In 
Sweden, the treatment completion rate in 2007 was on average 87% (87). In earlier randomized 
studies of HIV-negative patients with good adherence, nine months of INH was 90% protective 
against active TB (88). RIF alone or in combination with INH was even more effective (89). 
Hepatotoxicity is a feared adverse event (AE) associated with LTBI treatment. In adult persons 
without HIV infection treated with INH, hepatotoxicity appears in 5%, but in only 0.2-1.5% of 
patients treated with RIF alone or in combination with INH (88). The combination of INH and 
rifapentine has been shown to have a preventive effect similar to that of INH monotherapy but 
with fewer AEs and higher completion rates (90). LTBI treatment has been found to be cost-
effective in selected groups in low-endemic countries (RIF and rifapentine-containing 
regimens are even more cost-effective than INH alone) (84, 91). The numbers of persons 
needed to screen (NNS) and treat (NNT) for LTBI to prevent one case of active TB can be 
calculated over a certain time (usually 5 years). The NNS and NNT values in migrants in the 
UK and Norway have been shown to be generally high and vary substantially with the rate of 
TB in the region of origin (92, 93). The implication of this is that screening and treatment 
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should be restricted to persons with additional risk factors: young age, recent TB contact and 
immunosuppression.  
There is still little knowledge about LTBI treatment of patients exposed to MDR TB. 
Fluoroquinolones alone or in combination with ethambutol and/or with pyrazinamide have 
been tried. High treatment discontinuation rates due to AEs in persons taking pyrazinamide-
containing regimens have been described. No regimen has yet been fully evaluated, but 
randomized trials are ongoing (94). 
1.4.3 Latent TB and HIV 
Early introduction of ART is vital for the prevention of active TB in people living with HIV. 
Since 2014 the recommendation has been to start treatment at HIV diagnosis (44, 95). The 
WHO recommends treatment of LTBI in patients with HIV (2). Overall the intervention rate 
has been low worldwide. The WHO estimates that out of 30 million people living with HIV, 
fewer than 1 million individuals are treated for LTBI (36), mainly because of fear of AEs, but 
also for concern about the development of drug-resistant tuberculosis. Several studies in high 
incidence countries have shown that INH for six to nine months, or INH combined with 
rifabutin or rifapentine for three months, reduces TB death and active TB considerably, 
regardless of ART, also in patients who test negative for LTBI (85, 96). INH treatment did not 
cause more serious AEs than placebo, and three months of INH and rifapentine was as safe as 
nine months of INH (90, 97, 98). LTBI treatment has not been shown to select resistant TB 
strains (99). Rifapentine alone for one moth has recently been compared to nine months of INH 
in persons living with HIV in countries with a TB prevalence of >60/100,000 inhabitants. 
Rifapentine treatment was shown not to be inferior to INH for the prevention of active TB and 
TB mortality. The rifapentine group had a lower incidence of AEs and were more likely to 
complete treatment (100).  
Screening and treatment for LTBI in persons living with HIV has been shown to be effective 
and safe also in low-endemic settings and is recommended not only by the WHO but also by 
the European Centre for Disease Prevention and Control (ECDC) and the American Center for 
Disease Control and prevention (CDC) (101-103). The Public Health Agency of Sweden 
recommends LTBI treatment for patients with HIV, primarily those who have not yet started 
ART or who have low CD4⁺ cell counts, once active TB has been ruled out (83). 
Recommended treatment (depending on individual circumstances and concomitant 
medications, see below) (104):  
1. Daily INH with pyridoxine for 6-9 months  
2. Daily INH with pyridoxine and RIF/rifabutin for 3 months  
3. Once-weekly isoniazid and rifapentine for 3 months  
4. Daily RIF/rifabutin for 3 months  
The National Reference Group for Antiretroviral therapy in Sweden recommends neither 
screening nor treatment for LTBI in people infected with HIV, as the mandatory HIV 
monitoring system is considered sufficient for early detection and treatment of active TB (95).  
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1.5 ACTIVE TB 
1.5.1 Immunocompetent persons 
Active TB is a disease that occurs in someone infected with M.tb. It is characterized by signs 
or symptoms of active disease. It can appear either directly after infection, when it is called 
primary TB, or more often after the awakening of dormant bacilli, also called secondary TB 
(105). In the vast majority of cases, TB activation occurs within two years after primary 
infection (106). The most common form is pulmonary TB ranging from 70-90% in different 
settings (107). Symptoms of pulmonary TB are cough, fever, night sweats, weight loss and 
sometimes hemoptysis, dyspnea and chest pain. The infection is often localized in the apical 
segment of the lung lobe and starts as bronchiolitis. Mediastinal lymph node enlargement and 
pleural effusion are also common at an early stage. Later, cavitation and sometimes extensive 
lung destruction appears. (105). Extrapulmonary TB is a result of hematogenous dissemination. 
Either bacilli that have spread during primary infection, rest dormant and awaken, causing local 
infection, or bacteria disseminate during post-primary infection. Extrapulmonary TB can occur 
in all parts of the body but is most common in intrathoracic and cervical lymph nodes. Other 
common forms are pleuritis, bone and joint infection, genitourinary and intestinal TB, and 
central nervous system infection (108). (Miliary TB is described below). Persons from the 
African and Asian continents have been shown to be generally more likely to present with 
extrapulmonary manifestations than Europeans, and females are also overrepresented in this 
group. Genetic factors may explain some of these differences (109).   
1.5.2 Immunocompromised persons 
HIV infection gradually leads to CD4⁺-cell depletion and increased risk for both primary active 
TB and reactivation of latent infection. With a sinking CD4⁺ cell count, in untreated HIV 
infection, the ability to generate solid granulomas decreases and hematogenous spread of M.tb 
and disseminated, extrapulmonary disease becomes more common. Numerous small 
granulomas are formed in different organs. The radiological picture resembles millet seed, with 
1-to-4-mm rounded seed-like opacities, giving it the name miliary TB. Disseminated TB is a 
serious condition often manifested as pleuritis, pericarditis and meningitis with only vague and 
nonspecific symptoms such as chronic fever. In a meta-analysis of earlier studies from high- 
and low-incidence countries, the mortality rate in TB during TB treatment was 19% in persons 
living with HIV but 4% in persons without HIV (110). Advanced pretreatment 
immunodeficiency persistently increases the risk of TB, also after the introduction of ART 
(111). A higher risk of TB also remains in patients treated with ART but with ongoing HIV 
replication (112).  
Other forms of medical immunosuppression and immunocompromising diseases also affect 
the TB incidence. Patients treated with TNF antagonist therapy have up to 25 times higher risk 
of active TB (113), and those undergoing solid organ transplantation, 20-75 times higher risk 
(114), but also chronic corticosteroid treatment, chronic renal failure and hemodialysis, 
hematological malignancies and diabetes mellitus are known risk factors for TB activation (21).  
1.5.3 Diagnosis of active TB 
TB is diagnosed with a combination of microbiology, radiography and sometimes 
histopathology. Microbiological diagnosis of pulmonary TB consists of smear microscopy, 
polymerase chain reaction (PCR) and culture of sputum samples. In the absence of sputum 
production, samples from bronchial or gastric lavage are commonly used in high resource 
settings (108). HIV testing should be recommended to all patients with TB (115). 
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Sputum-smear microscopy is most commonly performed with Ziel-Neelsen staining using the 
acid-fast property of the bacteria. M.tb cannot be differentiated from NTM with this technique. 
The test is a cheap and simple and has been used worldwide since its invention by Robert Koch 
in 1882. It has since been improved with sputum sample centrifugation, auramine or rhodamine 
staining and fluorescent microscopy with LED light, used for analysis. A positive test requires 
at least one bacillus in a minimum of one examination of at least 100 microscopic fields, in one 
sputum sample from a TB suspect. The test has a low sensitivity compared to culture (25-75%) 
and a positive test requires 5000 bacilli per ml of sputum (116). Sputum smear-positive patients 
are seen as highly contagious (108). 
Polymerase chain reaction (PCR) is a line probe assay technique used to amplify certain DNA 
sequences. With this method, M.tb infection can rapidly be identified in smear-negative but 
later culture-positive patients. PCR has an acceptable sensitivity for sputum samples but it is 
inferior for other samples, especially fluids (cerebrospinal and pleural fluid) (117, 118). The 
PCR method should not be used for treatment control as dead bacteria can cause false positive 
results (119). The method can distinguish M.tb from most NTM-infections and can also be used 
to detect common mutations in genes coding for drug resistance (120). The Xpert MTB/RIF 
assay (Cepheid, Sunnyvale, CA, USA) is a point-of-care test for the detection of M.tb and signs 
of RIF resistance in sputum, giving a result within two hours. The method has replaced smear 
microscopy in many low-income settings. It improves diagnostic accuracy by 23% compared 
to microscopy alone, among culture-confirmed cases (121). 
In Culture, M.tb grows slowly, with a generation time of 18–24 hours. A specimen that shows 
no evidence of growth after 8 weeks is classed as negative. The gold standard for TB diagnosis 
is culture of mycobacteria, performed on solid egg-based (mostly Lövenstein-Jensen) and agar-
based media in parallel with broth-based liquid media. The advantage of solid media is their 
ability to reveal slow-growing bacteria, mixed cultures and contaminants. The combination of 
the two diagnostic culture methods renders fast and more accurate diagnosis, with about 80% 
sensitivity (122). After identification of mycobacterial growth, a chromatographic 
immunoassay or line probe assay is used to discriminate between M.tb complex and NTM. 
Conversion from positive to negative sputum culture within two months from treatment 
initiation is used as a sign of effective treatment in pulmonary TB. If this is achieved, relapse 
and failure are unlikely (123). However, sputum samples are often hard to obtain after two 
months, as many patients have improved significantly.  
Adenosine deaminase is an enzyme required for the proliferation and differentiation of 
T lymphocytes and the maturation of monocytes to macrophages. The enzyme is elevated in 
diseases associated with cellular immunity and is widely distributed in tissues and body fluid. 
The test is used as a diagnostic aid preferably in TB meningitis, pericarditis, peritonitis and 
pleuritis (124).  
Another diagnostic method involves detection of mycobacterial lipoarabinomannan (LAM) 
antigen. Lipopolysaccharide present in mycobacterial cell walls is released from metabolically 
active or degenerating bacterial cells. The antigen can be detected in urine from patients with 
active disease. In persons living with HIV with CD4⁺ cells ≤100 cells/μl, a positive urinary 
LAM test has high specificity (but a low sensitivity) for active TB. A positive test has also been 
shown to be associated with a high mortality in this group. As a substantial proportion of these 
patients have low sputum bacillary load, the point-of-care urine LAM test can be used as 
complement to sputum microscopy (125). Much effort is being made to further explore the 
LAM test for the diagnosis of active TB but also as a predictive biomarker of the outcomes of 
TB treatment and for the evaluation of treatment efficacy (126). 
Alternative biomarkers to improve immune diagnosis of TB and monitoring of treatment 
efficacy are under development. Promising results have been achieved with the chemokine, 
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IFN-γ-induced protein 10 (IP-10), produced by antigen presenting cells in patients with TB, 
irrespective of HIV status. IP-10 seems to be higher in patients with active TB than LTBI and 
decreases under active TB treatment. It might in the future be used to monitor therapy efficacy 
(81, 127).  
Radiography: Radiography is an important tool in the diagnosis of TB. In suspicion of 
pulmonary TB chest radiography (x-ray) can detect shadowing, caverns and enlarged 
mediastinal lymph nodes. Computer tomography (CT) scan is more sensitive than chest x-ray 
and detects minor abnormalities such as bronchiolitis (“tree-in-bud” phenomenon) and miliary 
TB. CT scan is also used for the diagnosis of extrapulmonary TB (18). Positron emission 
tomography (PET) CT is a relatively new tool used for the detection of active TB but can also 
assess therapy response. It measures the uptake of injected 18F-fluorodeoxyglucose (18F-FDG), 
in inflammatory cells. The site of infection is visualized with a CT scan (128). 
Histopathology: In microscopy, TB infection is visualized as granulomatous inflammation 
with aggregated macrophages, epithelioid cells and multinucleated giant cells formed around 
a necrotic center (18). The pattern is less characteristic in immunocompromised patients, for 
instance those with HIV co-infection. 
Detection of resistance: Culture-based phenotypic drug susceptibility testing on solid or in 
liquid media, is the standard method. It can detect and assess the degree of resistance to both 
first and second line drugs (129). As the method is slow (requiring 1-4 weeks), new methods 
have been invented the recent decades. PCR-based molecular techniques for rapid detection of 
gene mutations related to resistance are in use. The following genes are associated with drug 
resistance to the most used drugs in TB-treatment: RIF - rpoB; INH - katG/inhA/ahpC; 
fluoroquinolones - gyrA; injectable antibiotics (capreomycin, kanamycin, amikacin) – rrs; 
ethambutol – embB; and pyrazinamide - pncA (130). The semi-automated Xpert MTB/RIF 
assay (Cepheid, Sunnyvale, CA, USA) detects mutations in the genetic region of rpoB 
(indicating multi-drug resistance) in sputum, within 2 hours, with a high sensitivity and 
specificity (121). Whole Genome Sequencing (WGS) is a precise method for genotypic drug 
resistance analysis which has high concordance (95-96%) with culture-based methods (131, 
132). WGS is cheaper and faster (9 days) than culture-based methods but is only available at 
specialist centers (133). However it is important to remember that the relationship between 
mutations and phenotypic resistance is not completely known and they do not always overlap. 
In about 10% of phenotypically INH-resistant strains no mutation in either katG och inhA is 
found, indicating an existence of so far unknown mutations and resistance mechanisms. On the 
other hand mutations that are not expressed does not lead to resistance (130).   
1.5.4 Treatment of active TB (not pregnant, adults) 
TB must be treated with a combination of drugs, as monotherapy selects resistant M.tb 
subpopulations (134). Adherences to treatment is crucial for cure. Support and treatment 
supervision must be individualized to each patient. Directly observed treatment (DOT) or 
video-observed treatment is one option, but other forms acceptable to the patient and to the 
health system can be used (135). In Sweden drugs are often distributed in dosing boxes for 2 
weeks’ use, refilled at the TB clinic.  
1.5.4.1 Treatment of drug-sensitive TB 
TB treatment is designed to kill different subpopulations of M.tb isolates. Fast-replicating 
bacteria are rapidly killed by the bactericidal INH, but to eradicate slow-replicating bacteria, 
RIF and pyrazinamide are needed (136). The treatment regimen for sensitive M.tb infection is 
a combination of INH, RIF, pyrazinamide and ethambutol during the intensive phase for two 
months, followed by a four-month consolidation phase with RIF and INH (137). Ethambutol 
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is added to reduce the risk for treatment failure until susceptibility has been confirmed. In 
patients with TB meningitis, the treatment should be prolonged to 9-12 months, and in case of 
bone infection to 9 months (137). Appropriate serum level of anti-mycobacterial drugs is of 
major importance for treatment success and can be measured for most drugs. Corticosteroid 
treatment should be added in case of TB in the central nervous system.  
RIF, INH and pyrazinamide are metabolized by the cytochrome P450 enzyme system in the 
liver, rendering their potential hepatotoxic effect. Genetic polymorphisms affecting this system 
has been show to increase the risk of liver injury in certain populations (138). RIF is a potent 
inducer of the enzyme system affecting metabolism and thereby the systemic concentration of 
other drugs. This must always be considered when starting TB treatment in patients with 
polypharmacy. Rifabutin is a less potent inducer of the cytochrome P450 enzyme system and 
can therefore replace RIF in combination with ART (see below), warfarin and calcineurin 
inhibitors, among other drugs (139).  
1.5.4.2 Treatment of resistant TB  
In patients with confirmed RIF-susceptible and INH-resistant tuberculosis, treatment with RIF, 
ethambutol, pyrazinamide and levofloxacin is recommended for a duration of 6 months (140).  
In patients infected with M.tb resistance to one first line drug, other than INH, treatment is 
prolonged to 12-18 months and ethambutol or a fluoroquinolone replaces the inactive substance 
(137).  
Globally most MDR-TB patients are recommended a total treatment duration of 18-20 months 
or 15-17 months after sputum culture conversion. In recently published WHO 
recommendations, a 9-12-month regimen could be considered if resistance to fluoroquinolones 
and second-line injectable agents has been excluded (140). In high-income countries such as 
Sweden, the resistance pattern is often known and the treatment regimen can be suited 
thereafter. Shortened, all-oral, bedaquiline-containing treatment courses are under evaluation 
in trials (STREAM II) (141). The regimen should contain drugs presented in Table 1. All 
Group A agents and at least one Group B agent should be included to ensure that treatment 
starts with at least four TB agents likely to be effective, and at least three agents should be 
included for the rest of the treatment after bedaquiline is stopped (bedaquiline can be used only 
for six months). If only one or two Group A agents are used, both Group B agents are to be 
included. If the regimen cannot be composed with agents from Groups A and B alone, Group 
C agents should be added (140). Treatment monitoring and patient support is even more 
important for patients with MDR TB  
ART is recommended for all patients with HIV and drug-resistant TB requiring second-line 
TB drugs, irrespective of CD4⁺ cell count and as early as possible (within the first 8 weeks) 
following initiation of anti-TB treatment (140). 
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Table 1. Recommended drugs for MDR-TB treatment – 2019 WHO update 
Group Drug Adverse reaction 
A 
(include all if 
possible) 
Moxifloxacin/Levofloxacin Arthralgia, achilles tendon rupture, 
polyneuropathy 
Bedaquiline QT-prolongation, liver toxicity 
Linezolid Pancytopenia, polyneuropathy 
B 
(add both if possible) 
Clofazimine Reversible skin discoloration 
Cyclocerine OR Therizidone Neurotoxicity, psychiatric disturbances, 
neuropathy 
C 
(add when drugs 
from group A and B 
cannot be used) 
Ethambutol, Delamanide, Pyrazinamide, Imipenem-cilastatin, OR 
Meropenem/clavulanic acid, Amikacin, Ethionamide/Prothionamide, p-
aminosalicylic acid 
 
1.5.4.3 Adverse reactions  
Hepatotoxicity is the most common severe reaction with an incidence ranging between 2-30% 
in different populations (142-144). The incidence is higher in elderly, in Asian populations, in 
persons living with HIV, chronic viral hepatitis or with concomitant alcohol abuse or use of 
other drugs (143, 145). Hepatotoxicity is defined as elevated alanine aminotransferase (ALT) 
level to ≥3 times the upper limit of normal in the presence of hepatitis symptoms, or ≥5 times 
the upper limit of normal in the absence of symptoms. Patients should be closely monitored 
(137).  
Other common side effects are listed in Table 2. Some of them can be severe while others are 
disturbing but often tolerable with symptomatic treatment (137). To avoid neuropathy, 
pyridoxine is administered to patients treated with INH. For early detection of optic neuritis 
caused by ethambutol, vision and color perception are tested monthly in Sweden (146).  
Table 2. Adverse reaction of first-line TB drugs 
Drug Adverse reaction 
Rifampicin Rash, nausea, fever, hepatotoxicity, cytopenia, allergy, shock, acute renal 
failure 
Isoniazid Vertigo, nausea, headache, neuropathy, allergy, hepatotoxicity, depression 
Pyrazinamide Vertigo, nausea, hepatotoxicity, arthralgia, allergy, hyperuremic syndrome 
Ethambutol Hyperuremic syndrom, optic neuritis 
Serious AEs are more common with MDR treatment and appear in 17% with linezolid and in 
2% bedaquiline (140). The most common AEs are listed in Table 1.  
1.5.5 Treatment outcome 
According to the WHO the estimated TB cure rate for the 5.9 million new TB cases in the 
2016 global cohort was 82% (9). The death rate after completed TB treatment has been shown 
to be 3.8 times higher than in the general population in low-endemic, high-income settings 
(147).  
Pulmonary TB is regarded as cured if sputum is smear- or culture-negative the last month of 
treatment. If sputum samples cannot be produced, completed treatment is regarded as 
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successful by the WHO (137). Monitoring patients after completion of treatment is not 
recommended in the WHO guidelines, except for one-year post-treatment monitoring of 
drug-resistant TB (14). In Sweden TB patients are followed for TB relapse for 6-12 months 
after treatment completion, and longer in case of resistant TB.  
Recurrent TB is defined as episodes of TB occurring in a person after treatment completion 
and can be caused either by endogenous infection with the same strain (relapse), or by 
reinfection with a different strain (reinfection) (148). The relapse rate in low-endemic settings 
has been shown to be 0.4-7% (149-151). Genotyping is used to separate relapse from 
reinfection. Risk factors for recurrent infection have be shown to include male sex, low 
socioeconomic status, origin from a high-endemic region, diabetes mellitus, smoking, alcohol 
abuse, intravenous drug use, infection with a Beijing lineage strain, MDR TB and pulmonary 
cavitation and CD4⁺ cell depletion in persons living with HIV (152).  
 
1.6 GENOTYPING OF MYCOBACTERIUM TUBERCULOSIS 
Molecular typing of M.tb isolates detects disease transmission and clusters of TB cases and is 
an important part of the TB control strategy. Drug resistant M.tb isolates has been genotyped 
in Sweden since 1994 and drug-susceptible strains have also been included since 1998. The 
initial method was restriction fragment length polymorphism (RFLP) (153, 154) combined 
with spoligotying (155). In 2012 the genotyping method was changed to the faster, 
mycobacterial interspersed repetitive unit-variable number of tandem repeat (MIRU-VNTR) 
method (156) combined with spoligotying. These methods analyze and compare only 
standardized parts of the genome.  
Since 2016, WGS has replaced the methods previously used in Sweden. WGS has a higher 
discriminatory power than RFLP and MIRU-VNTR (157) and is as fast as MIRU-VNTR, 
generating a result within a month. With WGS, the genetic similarity between strains is 
measured in the numbers of single nucleotide polymorphisms (SNPs). M.tb has been reported 
to have a high genomic stability with a steady genetic turnover rate of around 0.3-0.5 SNPs per 
genome per year (158, 159). The SNP threshold, to define a TB cluster in epidemiologically 
linked cases and after recent transmission, has been established to a maximum of five SNP 
differences (132, 160). The use of WGS offers quicker contact tracing and more precise cluster 
investigations, which is important to limit transmission of the disease (157, 161). Efforts are 
being made to harmonize the nomenclature of WGS by the use of a reference strain comparing 
specific loci (160). 
In contact investigation, the connection between individuals is described in a minimum 
spanning tree. The degree of genetic dissimilarity between the bacterial strains they are infected 
with is used to link together the individuals that carry the most similar strains, indicating a 
possible transmission (162).  
WGS can also be used to distinguish relapse with the same M.tb strain from reinfection with a 
new strain in patients previously treated for TB. With earlier used techniques, reinfection was 
considered the main cause of recurrent infection in high-endemic countries (163, 164). In 
contrast, relapse was considered more frequent in low-endemic regions (152). As WGS has a 
higher resolution than previously used methods, some cases regarded as relapse based on the 
older genotyping methods, would be regarded as reinfection based on WGS results (157). Also, 
WGS has the capacity to better identify minority M.tb populations, as in infections with several 
strains, so-called mixed primary infection (165, 166).  
As mentioned, WGS can be used to identify mutations coding for drug resistance.  
 18 
1.7 TB-VACCINES 
1.7.1 BCG 
The BCG vaccine is weakened attenuated strains of Mycobacterium bovis, administered with 
an intradermal injection. It was developed at the Pasteur Institute in Lille, France in 1921. 
Continuous passaging has led to several substrains currently being in use. The strain divergence 
has not led to any significant variation in vaccine efficacy (167). BCG has shown an over 80% 
efficacy in preventing serious forms of disease, such as meningeal TB in children under the 
age of five (168, 169), but in adults the efficacy ranged from zero to 80% in different 
populations and its protective effect appears to decline with time (6). The effect of the vaccine 
varies with the geographic location. The protective effect has been shown to be stronger at 
higher latitudes, but closer to the equator the effect seems weaker (170). A placebo-controlled 
study conducted among native Americans in the 1930s showed significant protection against 
active TB  up to 40 years after BCG vaccination (171). More recent studies from the northern 
hemisphere confirm a vaccine effectiveness of 50-60% for 20 years and still 40% for another 
20-40 years (172, 173). Differences in the protective effect in various countries could be 
explained by the differences in initial protection. In TB-endemic areas, infection with M.tb 
prior to BCG vaccination may render a weaker immune response to the vaccine and therefore 
a lower protection rate (167). Continued and extensive exposure to NMT in warmer countries 
is another explanation for reduced BCG reactivity (174).  
The current global recommendation from WHO is to administer BCG vaccination at birth in 
TB-endemic countries (175). In countries with low rates of TB, selective vaccination is used 
under continuous disease surveillance (176). The Public Health Agency of Sweden does not 
recommend BCG vaccination of adults but only of children who come from a TB-endemic 
area, have a close relative with active TB, or who will be traveling for more than three months 
to or in TB-endemic areas where contact with locals is expected (177). Revaccination with 
BCG is not recommended, but recent studies have shown some evidence of reduced risk of 
M.tb infection after BCG revaccination (178). As BCG is a live vaccine, it is contraindicated 
in immunocompromised persons, such as people living with HIV, who are at heightened risk 
of hematogenous dissemination (176).  
1.7.2  New vaccines 
Three basic approaches for new TB vaccines are: 
 preventive, pre-exposure vaccines or priming vaccines, which are administered to 
neonates, prior to the first exposure to M.tb. The primary concept is to find a live 
vaccine to replace BCG, but subunit vaccines are also in clinical trials.  
 preventive post-exposure vaccines or boosting vaccines which are targeted to 
adolescents and adults with LTBI and prior BCG immunization. Inactivated live 
vaccines and subunit vaccines are in clinical trials.  
 therapeutic vaccines, administered with regular TB drugs.  
1.7.2.1 Live vaccines 
Inactivated whole-cell vaccine derived from a NTM is used as a boost vaccine for BCG-
vaccinated individuals. It has been shown to be safe, immunogenic and effective in phase 1, 2 
and 3 studies in TB endemic areas and has advanced to efficacy trials (179).  
Recombinant BCG (rBCG) has been developed both as a replacement for BCG vaccination in 
infants and as a TB vaccine in adolescents and adults. BCG strains are engineered by the 
insertion of virulence factors from other bacteria. For example in the VPM1002-vaccine 
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candidate a gene, derived from the bacteria Listera Monocytogenes, coding for listeriolysin O, 
has been inserted. Listeriolysin O perforate the lysosome, permitting the recombinant strain to 
escape from the macrophage lysosome into the cytosol and thereby the macrophage 
overexpress antigens which improve CD8+ T cell induction. It also induce autophagy and 
apoptosis (180). This vaccine candidate has been shown to be more effective in preventing 
active TB but less virulent than the original strains (55). It has been tried and proven safe in a 
phase 2 trial in HIV-infected and HIV-uninfected infants. A phase 3 trial is now being 
conducted in infants, and a phase 2b/3, randomized, double-blind, placebo-controlled trial is 
being conducted to assess the efficacy in preventing recurrence of TB in adults recently treated 
for and cured of active TB (181, 182).  
Live attenuated M.tb vaccines MTBVAC have been developed primarily to replace BCG as a 
priming immunization against TB in infants and has passed phase 1 trial. These M.tb strains 
have genetically manipulated genes coding for virulence factors permitting its survival in host 
cells. MTBVAC is also being assessed in safety studies, for use in previously BCG vaccinated 
adolescents and adults (181, 182). 
Alternative BCG strategies: in rhesus macaques, aerosol or intravenous administration of BCG 
has been shown to better induce a mycobacterium-specific immune response and reduce 
disease severity compared to intradermal injection (183). 
1.7.2.2 Subunit vaccines 
Subunit vaccines have been developed to boost BCG-derived immune response to provide a 
long period of protection. They are composed of several TB antigens that are considered 
immunogenic and protective (ESAT-6, CFP-10, TB10.4, Ag85A, Ag85B, Mtb32A, Mtb39A, 
and Rv2660c), combined with an adjuvant or a viral vector for increased immunogenicity. They 
are well tolerated and induce a sustained immune response in humans (184-186). 
In viral vectored vaccines M.tb antigens are combined with modified and attenuated vaccinia 
virus (pox virus), adenovirus or influenza virus for enhanced uptake and efficacy. The vaccine 
candidate MVA85A uses vaccinia as a vector, combined with Ag85A, and has been shown to 
be safe and immunogenic in a phase 2 trial but showed no significant efficacy against active 
TB in previously BCG vaccinated infants (187). As prime vaccination in HIV-exposed 
newborn children it induced a modest antigen-specific immune response (188).  
Recombinant cytomegalovirus vectors encoding M.tb antigen have been tested in animal 
models (189).  
In protein-adjuvant vaccines, a fusion of M.tb TB antigens is combined with an adjuvant (IC31, 
CAF01, AS01 or GLA-SE) that prolong antigen exposure and enhancing the uptake of antigens 
into antigen presenting cells and thereby stimulating immunity (190).  
The M72/AS01E vaccine consists of the antigens Mtb39A and Mtb32A combined with the 
adjuvant AS01E. The vaccine is intended to prevent TB in adults and adolescents. It has a 
clinically acceptable safety profile both in non-HIV-infected and HIV-infected individuals 
(191, 192). Recently the ability of the M72/AS01E vaccine to provide protection against active 
pulmonary TB disease in previously TB infected individuals (QFT-positive) was assessed in a 
randomized, double-blinded, placebo-controlled study (193). The trial was conducted on 3,330 
HIV-negative adults in TB-endemic countries. The vaccine provided 54% protection against 
active pulmonary TB-disease during 2.3 years of follow-up. No serious AEs were reported but 
more injection-site reactions and influenza-like symptoms were seen with active vaccine 
compared to placebo. 
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The H4:IC31 vaccine candidate consists of the antigens TB10.4 and Ag85B combined with the 
IC31 adjuvant and has been shown to be safe and immunogenic in phase 1 trials (184, 185). 
The vaccine was included in a phase 2 study in South Africa, published 2018 (178). Almost 
1,000 QFT-negative young adults were vaccinated twice with either H4:IC31, BCG or placebo 
and followed regularly for QFT conversion for 24 months. Neither vaccine prevented initial 
QFT conversion but both vaccines showed a significantly reduced rate of sustained QFT 
conversion. The sustained conversion was 8.1% in the H4:IC31 group and 6.7% in the BCG 
group, as compared with 11.6% in the placebo group. These findings may reflect a reduction 
of sustained M.tb infection. There were no clinically significant differences in the rates of 
serious adverse events between the groups.  
H56:IC31 is a vaccine composed of Ag85B, ESAT-6 and Rv2660c with the IC31 adjuvant. It 
has been developed to prevent TB disease at all ages and to prevent recurrent TB. Phase 2 trials 
testing its ability to serve as adjunctive immunotherapy and thereby shortening the treatment 
duration for active TB are ongoing (182). 
Studies employ different protocols and methods to measure Th1-cytokine expression and the 
entailed level of protection is uncertain, which makes comparisons problematic. With that 
caveat, it can be noted that the M72/AS01E induced the highest memory CD4⁺ T cell response 
(59). Overall, a better correlate of protective TB immunity would facilitate assessment of 
disease prevention and also promote consistency in immunogenicity measures comparing 
different trials.  
1.7.2.3 Therapeutic vaccines 
The therapeutic vaccines are used as immunotherapy and are thus not regular vaccines but 
rather therapy adjuncts.  
Heat-inactivated M vaccae, available in injectable and oral forms, has been shown to shorten 
the time to sputum conversion and radiographic resolution in patients with pulmonary TB by 
activating the Th1 cytokine-mediated immune response and macrophage phagocytosis. It has 
been shown effective as adjuvant therapy with general chemotherapy for the treatment of 
MDR-TB and has been approved for this purpose for patients in China (194).  
A phase 2 trial with aerosol administration of NTM (M. indicus pranii) as an adjunct to TB 
treatment is ongoing (195). 
RUTI is composed of detoxified, inactivated, latency-associated M.tb antigens. These antigens 
are hidden during the active phase of TB and therefore not recognized by the immune system. 
After immunization with RUTI the immune system also attacks dormant bacilli. The vaccine 
has been tried for the prevention of active TB. Given as a subcutaneous injection after a total 
of one month of LTBI treatment, it has been shown to induce a specific cellular but also a 
strong humoral immune response. It has been shown safe in phase 2 trials, including patients 
living with HIV (189).  
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2 AIMS 
2.1 GENERAL AIMS 
The general aim of this thesis is to increase the knowledge of TB and especially TB-HIV co-
infection, with an emphasis towards prevention, in a low-endemic setting in an area of 
increasing migration from TB-endemic countries. 
2.2 SPECIFIC AIMS 
2.2.1 Paper I 
To identify factors associated with anti-TB treatment success as well as adverse drug reaction 
in HIV-TB-co-infected persons in the era of ART. 
2.2.2 Paper II 
To test the safety and immunogenicity of the new TB vaccine in a prime-boost vaccination 
strategy in healthy, previously BCG-vaccinated individuals. 
2.2.3 Paper III 
To understand the usefulness of chemoprophylaxis among people living with HIV in a low-
endemic setting today. 
2.2.4 Paper IV 
To evaluate current treatment strategies and treatment control in Stockholm County by 
analyzing of the respective frequency of relapse and reinfection. 
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3 MATERIALS AND METHODS 
3.1 STUDY SUBJECTS AND METHODS 
3.1.1 Paper I 
3.1.1.1 Setting and data collection 
All adult patients (aged ≥18 years) diagnosed with both HIV and TB in Stockholm County, 
1987-2010 were identified in the Swedish national quality registry named InfCare HIV. TB 
diagnosis was defined as symptoms and laboratory findings leading to TB treatment. The 
criterias for TB diagnosis was fullfiled in 127 patients. In 109 patients (86%), TB was 
confirmed confirmed. In the remaining 18 patients, diagnosis was based on PCR, clinical, 
radiological, or histopathological signs suggestive of TB which responded to treatment. Data 
related to demographic characteristics and HIV/AIDS (acquired immunodeficiency syndrome) 
status were collected from InfCare HIV, the Swedish TB registry (containing data on all cases 
of active TB in Sweden) and from medical records.  
3.1.1.2 Definitions 
 The clinical manifestation of TB was defined as:  
o “Isolated pulmonary” if TB involved only the lungs. 
o “Extrapulmonary” if TB was diagnosed in organs other than the lungs, 
including lymph nodes and pleura. 
o “Disseminated” if at least 1 extrapulmonary site and the lungs were 
involved. 
 Anti-TB treatment was classified as first-line or second-line, based on the choice 
of drugs according to the WHO guidelines (137). 
 Antiretroviral treatment was classified as ART if consisting of NRTIs combined 
with a PI, non-nucleoside reverse-transcriptase inhibitors (NNRTI), or fusion 
inhibitor (FI); or at least 3 NRTIs according to the Swedish recommendation for 
the treatment of HIV infection in 2009 (196). 
 Adverse reactions were defined as severe, noxious or unintended responses to 
anti-TB treatment that led to treatment discontinuation or modification, based on 
the judgment of the attending physician.  
 Outcomes of anti-TB treatment were defined as: 
o “Successful” for patients who were cured or completed treatment without 
any registered TB recurrence within the follow-up period until the end of 
2011. 
o “Unsuccessful” in the case of death due to the primary diagnosed TB 
infection or death irrespective of reason during the TB treatment period, 
or discontinued treatment. 
o “Not evaluated” in the case of transfer to another clinic before treatment 
completion. 
3.1.1.3 Study design 
Because of the introduction of ART in 1996 the cohort was stratified into two cohorts: the early 
cohort (1987-1995) and the late cohort (1996-2010). Sociodemographic and clinical 
characteristics were compared for the two cohorts. ART was evaluated as possible predictor of 
a successful anti-TB-treatment and of adverse reactions.  
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3.1.2 Paper II 
A new TB vaccine candidate, H4:IC31 composed of the H4 antigen which is a fusion protein 
created from two M.tb antigens Ag85B and TB10.4, and an immunological adjuvant called 
IC31® was evaluated in two phase 1 randomized, double-blind, placebo-controlled studies , in 
Stockholm and in Finland.  
3.1.2.1 Inclusion criteria  
Previously BCG-vaccinated (≥5 years), males or females (females required to be sterilized), 
age 18-50 years, HIV-uninfected, good health based on medical history, normal body mass 
index (19-33), no evidence of an ongoing TB infection and written informed consent 
completed.  
Both studies employed vaccine dose escalation, with increasing amounts of the H4 antigen 
administered in the presence of increasing amounts of the IC31 adjuvant Table 3. Formulation 
buffer was used as placebo control. Subjects received vaccinations via intramuscular injection 
on study days 0 and 56. Treatment assignments were based on a randomly generated sequence 
of subject identification numbers on a randomization schedule. 
Table 3. A dose matrix of the H4 and IC31 dose combinations administered to the study 
subjects in the C-005-404 and C-006-404 trials* 
 One vaccination 
Day 0 
Two vaccinations 
Day 0 and 56 
 
H4 dose 50 g 150 g 5 g 15 g 50 g 150 g 
Total 
(n=124) 
No adjuvant 8 8 --- --- 8 --- 24 
100 nmol IC31 8 --- 9 9 8 --- 34 
500 nmol IC31 8 --- 8 8 16** 8 48 
Placebo --- 18*** 18 
* A total of 124 participants were included in the two trials. **Two doses of 50 g H4 in 500 nmol IC31 were 
administered to 8 participants in each of the C-005-404 and C-006-404 trials. ***A total of 18 participants 
received two placebo vaccinations in the two trials. 
3.1.2.2 Adverse events 
Safety evaluation of the H4:IC31 vaccine treatment regimens was based on the induction of 
AEs that represented both clinical and laboratory evaluations. We recorded solicited AEs 
(derived from the study subject’s diary, from physical examination and laboratory results) and 
unsolicited AEs (spontaneously reported by the subject) during the first 28 days after each 
vaccination and serious AEs (SAEs) during the 6-month study period. 
 
AE severity was graded according to the US Food and Drug Administration (197) as:  
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 Mild (Grade 1), no medical intervention required 
 Moderate (Grade 2), requiring outpatient medical intervetion 
 Severe (Grade 3), requiring prolonged medical intervention and/or 
hospitalization  
 Potentially life-threatening (Grade 4), requiring hospitalization with intensive 
care 
3.1.2.3 Immunogenicity testing 
Subjects were screened for ongoing TB infection using QFT and the TST. Peripheral blood 
mononuclear cells (PBMC) were isolated from blood collected on study days 0, 7, 14, 28, 56, 
63, 70, 84, and 182 for intracellular cytokine staining (ICS) and on study days 0, 56, 84, and 
182 for assessment of M.tb-specific IFN-γ production using ELISpot. In study C-005-404, 
blood was also collected on study days 0, 7, 28, 63, 84, and 182 for Flow-cytometric Assay for 
Specific Cell-mediated Immune-response in Activated whole blood assay (FASCIA).  
3.1.3 Paper III 
3.1.3.1 Study population 
The study included all adult patients (aged ≥18 years) diagnosed with HIV at Karolinska 
University Hospital in Stockholm, from January 1996 through December 2013. The patients 
were identified in InfCare HIV, and data on; sex, year of birth, route of HIV transmission, 
country of origin, date of HIV diagnosis, HIV viral load and CD4⁺ count at HIV diagnosis, 
CD4⁺ nadir (during the study period) and, where applicable, date of death, we extracted from 
the registry. For patients who were diagnosed with TB during the study period additional data 
were extracted: date of TB diagnosis, CD4⁺ count and HIV RNA viral load at TB diagnosis, 
date for ART initiation and ART regimen. Information on TB manifestation, diagnostic 
procedures and treatment regimens was retrieved from the national reporting system and 
registry, SmiNet and medical records.  
The patient cohort was divided into two groups, based on the year of HIV diagnosis (1996-
2008 and 2009-2013) due to the changed guideline recommendations for the introduction of 
ART in 2009. During the first part of the study period (1996-2008), guidelines recommended 
ART for patients with a CD4⁺ count of 250 cells/μl or less; in the later part of the study period 
(2009-2013), guidelines recommended ART for patients with a CD4⁺ count under 350 cells/μl.  
3.1.3.2 Definitions of terms and concepts 
 Active TB was defined as a specimen positive for acid fast bacilli in smear 
microscopy or PCR or culture for M.tb or if radiography or histology was 
characteristic for active TB and led to treatment for active TB. 
 TB diagnosed within one month from HIV diagnosis was assumed not to have been 
preventable with LTBI-treatment and was defined as early TB. In contrast, TB 
diagnosed more than one month after HIV diagnosis was considered to have been 
potentially preventable with LTBI-treatment and was defined as late TB in coherence 
with previous studies (198, 199). Patients were considered to be at risk of preventable 
TB from one month after HIV diagnosis until TB diagnosis or death or end of follow-
up.  
 Country of origin was classified as TB-endemic versus low-endemic, based on the 
WHO estimates of TB incidence in different countries (36). Based on these estimates, 
countries in sub-Saharan Africa and Asia were classified as TB-endemic and all other 
countries as low-endemic. 
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 Clinical manifestation of TB was defined as isolated pulmonary if only the lungs 
were affected; extrapulmonary if other organs than the lungs were affected, including 
the pleura and thoracic lymph nodes, or disseminated if the lungs and at least one 
extrapulmonary site were involved.  
 In patients from TB-endemic countries, latent TB was considered possible in absence 
of regular TST or IGRA test results. 
 CD4⁺ nadir was defined as the lowest CD4⁺ value measured within the study period.  
 ART was defined as a combination therapy involving two NRTIs plus one of the 
following: a PI, a NNRTI, or a fusion inhibitor (FI). 
 ART was classified as: possibly effective if ART had been administered for more than 
3 consecutive months; or confirmed effective if ART had been administered for more 
than 3 consecutive months and HIV-RNA was undetectable (<50 copies/ml) (95). 
 
3.1.4 Paper IV 
3.1.4.1 Setting and data collection 
All TB cases diagnosed in Stockholm County, from January 1996 through December 2016, 
were identified in the national reporting system and SmiNet-registry. Only cases with culture 
confirmed M.tb infection were eligible for inclusion, and were followed for TB recurrence until 
the end of 2017. Demographic and clinical data and microbiological results were also extracted 
from the registry. For patients with recurrent TB, information on risk factors for recurrence was 
retrieved from individual patients’ files. Information on HIV co-infection was obtained from 
the Swedish national quality registry (InfCare HIV). WGS was performed on the M.tb strains 
in cases with TB recurrence to distinguish relapse from reinfection, and SNP variants were 
compared between the TB episodes. 
3.1.4.2 Definitions 
 A case of TB recurrence was defined as a patient, previously successfully treated for 
TB, who had a new TB episode more than 180 days after treatment completion. 
 Treatment success was defined as cure or treatment completion according to the 
WHO definitions (200, 201). 
 The anatomical site of TB disease was defined as pulmonary, extrapulmonary or 
disseminated according to the WHO definitions (201). 
 The patient’s country of origin was regarded as endemic if it had a TB incidence of 
≥100/100,000 population and as low endemic if <100/100,000 (9).  
 A relapse case was defined as a maximum difference of five SNPs. 
 M.tb resistance was defined as mono-drug resistance or MDR resistance, according to 
the WHO definitions (200, 202). 
3.1.4.3 DNA extraction, whole genome sequencing and detection of resistance mutations 
DNA was extracted from M.tb strains and subsequently quantified (153, 203). The 
sequencing reads were compared with a reference genome. The similarity between isolates 
from the same patient was studied by SNP analysis. A distance matrix was calculated and the 
relatedness was visualized in a minimum spanning tree (162). In order to detect resistance 
mutations, the sequencing reads were mapped against a set of resistance genes (rpoB, katG, 
inhA, embB, pncA, gyrA, gyrB, rrs, eis, tlyA and ethA) derived from a reference genome.  
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4 STATISTICAL ANALYSIS 
 
In general a p-value of <0.05 was considered significant for all studies and all tests were two-
sided.  
Descriptive statistics were used to analyze sociodemographic and clinical data and are 
presented as medians and interquartile ranges (IQR) for numeric variables and as percentages 
for categorical variables. Comparisons between groups were performed using the Mann-
Whitney U-test for continuous variables. A Chi-square test, or where appropriate Fisher’s exact 
test, was used for categorical variables. Study I, III and IV. 
In Study I and IV we used logistic regression analysis to estimate associations of patient 
characteristics with outcome variables. In Study III a Cox proportion hazard regression model 
was used to analyze risk factors for active TB over time.  
In Study III the incidence rates were calculated as the annual number of patients diagnosed 
with TB divided by the annual number of person-years at risk. Trends in incidence rates were 
calculated using a Poisson regression model presented as percent change in incidence rate per 
year.  
In Study III the number needed to treat (NNT) for latent TB, to avoid one case of active TB, 
was calculated as the reciprocal of the incidence of TB (the number of TB cases/the number of 
patients at risk for TB). 
In Study II the sample size for each trial was calculated as adequate for the assessment of the 
safety profile. Basic descriptive analyses were used to examine AEs and immune response for 
each treatment regimen and area under the curve (AUC) analyses were made for comparison 
of the different immune responses to different treatment regimens. Overall p-values for median 
AUC among treatment regimens were obtained using the Kruskal-Wallis test. Pairwise 
comparisons of median AUC between treatment regimens were conducted using a Mann-
Whitney exact test. The Holm method was used for correction of multiple comparisons, 
reducing the risk of type I error. 
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5 RESULTS AND DISCUSSION 
5.1 PAPER I 
5.1.1 Results 
The study included 127 patients with HIV and TB co-infection, of whom 26 were stratified 
into the early cohort (1987–1995) and 101 into the late cohort (1996–2010). A majority of the 
patients were originally from a country other than Sweden, mainly from sub-Saharan African 
countries (85% in the early cohort and 88% in the late cohort). There was a significant increase 
in female patients from 26% (n=6) in the early cohort to 49% (n=49) in the late cohort (p=0.02). 
Over 40% of patients in both cohorts were diagnosed with TB within 6 months from their HIV 
diagnosis.  
5.1.1.1  Antiretroviral treatment 
In the early cohort none of the patients received antiretroviral treatment classified as ART but 
13 (50%) were treated with single or dual NRTIs.  
In the late cohort, 76/101 patients (76%) were treated with ART during the TB treatment 
period. ART was initiated before TB-diagnosis in 31 patients. A PI-based regime was used in 
53 patients. The percentage of patients who received ART was highest among those with 
disseminated TB, 90% (35 of 39), compared to 64% (14 of 22) among those with 
extrapulmonary TB and 68% (27 of 40) among those with isolated pulmonary TB (p = 0.026).  
5.1.1.2 Anti-TB treatment  
The percentage of patients who completed their anti-TB treatment successfully increased from 
65% in the early cohort to 91% in the late cohort (p=0.002). Sixteen patients (62%) in the early 
cohort and 77 patients (76%) in the late cohort received anti-TB treatment with ﬁrst-line TB 
drugs. Three patients (12%) in the early cohort and 10 patients (10%) in the late cohort had 
single-drug resistant M.tb strains and 2 patients (2%) in the late cohort had MDR TB. In non-
MDR TB cases the drug regimen was based on RIF in 58 patients (59%) and rifabutin in 41 
patients (41%). Of those on RIF, 21 patients (36%) switched to rifabutin on initiation of ART. 
The median duration of successful anti-TB treatment among patients with drug-susceptible TB 
(n=94), excluding 6 patients with TB in the central nervous system, was 8 months (IQR 6 – 27) 
in the early cohort (n=11) and 8 months (IQR 6 – 10) in the late cohort (n=77). 
5.1.1.3  Adverse reactions to anti-TB treatment in the late cohort 
Out of 99 patients in the late cohort whose treatment outcomes were evaluated, 23 (23%) 
suffered from adverse reactions severe enough to lead to modiﬁcation of anti-TB treatment. 
Twenty-two (96%) of these patients were on concomitant ART, Figure 5: 3 patients were on 
ART at the time of TB diagnosis and 19 initiated ART at a median 2 months (IQR 0.7 – 3.5) 
after TB diagnosis. All 23 patients with adverse reactions completed treatment successfully 
after a median 11 months (IQR 9.0 – 13.5). The reported adverse reaction manifestations were: 
affected liver function (n=8; 2 of whom had chronic hepatitis C), neurological complications 
(n=5), IRIS (n=3), affected vision (n=3), rash (n=3), renal complications (n=1), joint pain 
(n=1), gastrointestinal complications (n=1), and other complications (n=2). 
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Figure 5. Dot plot representing the occurrence/non-occurrence of adverse reactions to 
anti-TB treatment in relation to the CD4 cell count (cells/μl) at the time of TB diagnosis 
among HIV-infected patients diagnosed with TB 1996 or later ( n=99). Three groups are 
compared. The dotted horizontal line represents the cut-off level for immunosuppression, 
which was speciﬁed at CD4 ≤200 cells/ μ l.  
 
5.1.1.4  Predictors of treatment success and adverse reactions in the late cohort 
In the multivariate logistic regression analysis (Table 4), treatment success in the late cohort 
was positively associated with ART (OR 13.3, 95% CI 1.5 – 114.8; p=0.018) and a CD4⁺ cell 
count >200 cells/μl (OR 17.2, 95% CI 1.2 – 236.6; p=0.034). The occurrence of adverse 
reactions in the late cohort was positively associated with the initiation of ART after TB 
diagnosis (OR 13.3, 95% CI 1.6 – 112.4; p=0.018). 
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Table 4. Results of logistic regression analysis: factors related to treatment success and 
adverse reactions to anti-TB treatment for patients with HIV and TB, diagnosed 1996 or 
later (n=99). 
 Successful treatment outcomes (n=99) 
 Yes (n=92) No (n=7) Bivariate analysis  
Multivariate 
analysis 
Variables n (%) n (%) OR (95% CI) OR (95% CI) 
ART     
Yes 72 (78) 3 (43) 4.8 (1.0-23.2) 13.3 (1.5-114.8)* 
No 20 (22) 4 (57) Reference  
Sex     
Female 47 (51) 1 (14) 6.3 (0.7-54.1) 5.9 (0.5-71.1) 
Male 45 (49) 6 (86) Reference  
Age at TB diagnosis, y     
≤37 57 (62) 1 (14) 9.8 (1.1-84.6)* 9.8 (0.9-105.0) 
>37 35 (38) 6 (86) Reference  
CD4⁺ count at TB diagnosis, cells/µl     
≤200 51 (55) 6 (86) Reference  
>200 41 (45) 1 (14) 4.8 (0.6-41.7) 17.2 (1.2-236.6)* 
  Adverse reactions to anti-TB treatment (n=99) 
 Yes (n=23) No (n=76) Bivariate analysis 
Multivariate 
analysis 
Variables n (%) n (%) OR (95% CI) OR (95% CI) 
ART     
ART before TB diagnosis 3 (13) 27 (36) 2.6 (0.2-26.3) 2.8 (0.3-29.3) 
ART after TB diagnosis 19 (83) 26 (34) 16.8 (2.1-135.6)** 13.3 (1.6-112.4)* 
No ART 1 (4) 23 (30) Reference  
Sex     
Female 13 (57) 35 (46) 1.5 (0.6-3.9) 1.0 (0.3-3.0) 
Male 10 (44) 41 (54) Reference  
Age at TB diagnosis, y     
≤37 18 (78) 40 (53) 3.2 (1.1-9.6)* 2.7 (0.8-9.0) 
>37 5 (22) 36 (47) Reference  
CD4⁺ count at TB diagnosis, cells/µl     
≤200 18 (78) 39 (51) 3.4 (1.2-10.1)* 1.8 (0.5-6.2) 
>200 5 (22) 37 (47) Reference   
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5.1.2 Discussion 
This study confirms what is well known worldwide: that the introduction of ART in 1996 
thoroughly changed life for persons living with HIV and so also the outcome of TB treatment 
in this group. In low-endemic settings, such as Stockholm, TB is largely a disease affecting 
persons from TB-endemic countries. Changes in the immigrating population are therefore 
reflected in the group of patients diagnosed with TB. The increasing proportion of women in 
the late cohort was accounted for by patients migrating from sub-Saharan Africa and Asia.  
We observed that most cases of adverse reactions occurred in patients who initiated ART after 
TB diagnosis, especially patients with a low baseline CD4⁺ cell count. The association was not 
statistically significant in a multivariate regression analysis but has been shown to be related in 
earlier studies. As expected the most frequently noted adverse reactions were effects on liver 
function and neurological complications. The vast majority of patients in our late cohort were 
treated with PI in combination with two NRTIs combined with a rifabutin-based TB regime, 
which can have influenced the incidence and panorama of AEs. Current national Swedish 
national guidelines (as of 2018) for treatment of HIV, recommend an efavirenz-based regimen 
in combination with RIF or an integrase inhibitor (INI)-based regimen with rifabutin (204). 
The INI regimens have fewer AEs compared to both PI and efavirenz, and the changed 
recommendations may have entailed an improvement for HIV and TB co-infected individuals 
(205, 206). 
Our study might have underestimated the frequency of IRIS. Some of the patients’ symptoms 
regarded as AEs can very well have been IRIS. Our definition of IRIS was that the physicians 
in charge note IRIS as an explanation for the patients’ symptoms in medical records. There 
might be a tendency to underreport IRIS as the cause of symptoms, as there are no consensus 
definitions for IRIS.  
 
5.2 PAPER II 
5.2.1 Results 
We enrolled 125 individuals and randomized them into the different intervention groups. In the 
Swedish study, all 64 randomized subjects received the vaccination on study day 0 and all 
completed the study. In the Finnish study, 60 of 61 randomized subjects received the 
vaccination on study day 0 and all subjects except two completed the study.  
5.2.1.1 Adverse events 
The majority (83%) of subjects across both studies had AEs graded as mild or moderate. Table 
5A and B. Severe AEs were noted in 18 (15%) subjects of which four were considered related 
to the study vaccine: fever, increased protein in urine, TST site reaction, and increased 
international normalized ratio (INR). The overall incidence and severity of the AEs did not 
differ between active vaccine and placebo. Four SAEs were reported [mental status changes 
(50/0 one dose regimen), mesenteric lymphadenitis (50/500 two dose regimen), ileus (50/500 
two dose regimen) and subdural hemorrhage (placebo)], none of which was considered related 
to study vaccination. 
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Table 5A. Adverse Events by Highest Severity for Each Subject: C-005-404 (Swedish 
study). 
 
 
 
 
Severity 
 
 
Placebo 
H4:IC31 (μg H4/nmol IC31) 
50/0 50/100 50/500 150/0 
1 Dose 2 Doses 1 Dose 2 Doses 1 Dose 2 Doses 1 Dose 
(n=8) 
n (%) 
(n=8) 
n (%) 
(n=8) 
n (%) 
(n=8) 
n (%) 
(n=8) 
n (%) 
(n=8) 
n (%) 
(n=8) 
n (%) 
(n=8) 
n (%) 
Mild 3 (37.5) 4 (50.0) 2 (25.0) 4 (50.0) 2 (25.0) 1 (12.5) 2 (25.0) 1 
(12.5) 
Moderate 4 (50.0) 2 (25.0) 5 (62.5) 2 (25.0) 4 (50.0) 6 (75.0) 4 (50.0) 4 
(50.0) 
Severe 1 (12.5) 1 (12.5) 1 (12.5) 2 (25.0) 2 (25.0) 1 (12.5) 2 (25.0) 3 
(37.5) 
Table 5B. Adverse Events by Highest Severity for Each Subject: C-006-404 (Finnish 
study). 
 
 
 
 
Severity 
 
Placebo 
2 Doses 
H4:IC31 (μg H4/nmol IC31) 
5/100 5/500 15/100 15/500 50/500 150/500 
2 Doses 2 Doses 2 Doses 2 Doses 2 Doses 2 Doses 
(n=10) 
n (%) 
(n=9) 
n (%) 
(n=8) 
n (%) 
(n=9) 
n (%) 
(n=8) 
n (%) 
(n=8) 
n (%) 
(n=8) 
n (%) 
Mild 4 (40.0) 3 (33.3) 4 (50.0) 3 (33.3) 2 (25.5) 1 (12.5) — 
Moderate 5 (50.0) 6 (66.7) 3 (37.5) 5 (55.6) 5 (62.5) 6 (75.0) 6 (75.0) 
Severe — — 1 (12.5) 1 (11.1) 1 (12.5) — 2 (25.0) 
 
Among solicited AEs, myalgia, arthralgia, and fever occurred at a higher frequency in subjects 
who received the active vaccine compared to placebo. Pain at the injection site was increased 
in subjects who received IC31 adjuvant. Among the first 21 included (all TST negative) 
subjects in the Swedish study, 14 experienced some degree of inflammation at the site of 
screening TST injection, after the first vaccination. The reactions were elicited by the H4 
antigen alone (78.6%) or H4 combined with a low dose of IC31 adjuvant (21.4%). One subject 
experienced a severe reaction at the TST site with onset the day of the first study vaccine 
administration. This subject had no screening TST reactivity or a reaction at the vaccine site.  
5.2.1.2 Immunogenicity 
In each of the H4:IC31 two dose regimens, the study vaccine induced Ag85B-specific but 
also TB10.4-specific CD4+ T cell responses, with a boosting effect seen after administration 
of the second dose. The strongest and most long-lived median CD4+ T cell responses 
compared to placebo were seen after stimulation with Ag85B in the 5/500 (p<0.01), 15/500, 
and 50/500 (p<0.01) two-dose regimens. These results were supported by the whole blood 
FASCIA assay, where the two-dose 50/500 treatment was shown to induce significant 
expansion of Ag85B-specific CD4+ T cells (p=0.02) and CD8αα+ T cells (p<0.001) compared 
to the two-dose placebo regimen. IFN-γ ELISpot responses to both Ag85B and TB10.4 were 
elevated, but only for the two-dose regimens together with the IC31 adjuvant. Figure 6. ICS 
analysis of Ag85B-specific CD4+ T cells at 4 weeks after the second vaccination (study day 
84) confirmed that only the two-dose treatment regimens efficiently induced cytokine 
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producing cells, primarily bi-functional IL-2/TNF-α producing and multifunctional IFN-
γ/IL-2/TNF-α producing T cells. 
  
Figure 6. H4:IC31 vaccination induces antigen-specific IFN-γ production in peripheral T 
cells from BCG-vaccinated study subjects. Frequencies of Ag85B-specific IFN-γ 
producing T cells induced by the H4:IC31 vaccine were measured using the IFN-γ 
ELISpot assay after stimulation of PBMCs with M.tb antigen-peptide pools. Expression 
of IFN-γ in Ag85B-specific T cells is shown for the different treatment regimens at study 
days 0, 56, 84 and 182 in study C-005-404 one dose (A) and two dose (B) regimens and C-
006-404 (C). The data illustrate medium-subtracted spot-forming cells per 106 PBMCs 
for all vaccinated subjects. Data are presented in linear graph plots showing the median 
and IQR for each group. 
5.2.2 Discussion 
This phase 1 study demonstrates that the H4:IC31 vaccine candidate is safe in healthy and 
previously BCG-vaccinated individuals. The local and systemic AEs were mild to moderate 
and did not increase in frequency or severity with a second vaccination. The highest H4 antigen 
dose (150 μg) induces systemic, solicited AEs (myalgia, arthralgia and fever) at a higher 
frequency. The AEs resolved within three days. A high dose of IC31 adjuvant caused 
significantly more injection site reactions. These findings have been confirmed in later and 
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larger phase 1 and 2 studies in high-endemic settings (178, 207). A post-vaccination 
inflammatory reaction was observed at the TST injection site in some of the subjects screened 
with TST at inclusion. The reaction appeared mostly in patients given only H4, without 
adjuvant. This delayed hypersensitivity reaction is caused by PPD-specific T cells rapidly 
migrating to the TST site in response to vaccine antigens that are also present in PPD. A similar 
reaction was observed with another vaccine candidate (Mtb72F/AS02) (208). This reaction 
needs to be considered in future trials. 
We could show that two doses of H4:IC31 vaccine induce a stronger CD4+ T cell, CD8αα+ T 
cell and IFN-γ response than a one-dose regimen or placebo. The effect was most pronounced 
after stimulation with Ag85B. These findings were later confirmed in a phase 1 study of the 
same vaccine candidate, in South Africa 2015 (207). A low dose of antigen combined with a 
high dose of adjuvants induced the strongest response. This may be explained by the fact that 
at a low dose, the antigen selectively induces a higher number of multifunctional T cells. This 
has earlier been associated with considerably stronger protection against subsequent M.tb 
challenge in mice (209).  
The more recent study (described above) of the H4:IC31 vaccine, given in the dose; H4, 15 µg 
and IC31, 500 nmol, to former BCG vaccinated adolescents, in a TB high-endemic setting, 
showed a significant reduction of sustained QFT conversion. This result indicates that the 
vaccine candidate might render some degree of protection against M.tb (178). The results are 
encouraging for the future prospects of subunit TB vaccines but in its current formulation, it is 
seems not be the ultimate solution for the global epidemic.  
  
5.3 PAPER III 
5.3.1 Results 
5.3.1.1 Patient characteristics  
During the study period 1,868 patients were followed from HIV-diagnosis until TB diagnosis 
or death or until the end of observation period. During the study period 92 patients (5%) in the 
cohort were diagnosed with TB. The median age at HIV diagnosis was 36 years (IQR, 29–44). 
The majority of the patients were men (58%). Most had acquired HIV through heterosexual 
transmission (65%) and were originally from TB-endemic countries (52%). Patients diagnosed 
with TB during the study period had a significantly lower median nadir CD4⁺ and median CD4⁺ 
at HIV diagnosis (p<0.001) and a significantly higher HIV viral load (p<0.001). Of the 92 
patients who were diagnosed with TB, six patients (7%) died, whereof two from TB. The 
proportion of patients from TB-endemic regions increased significantly over the study period 
(1996-2001: 45%, 2002-2007: 53%, 2008-2013: 58%, test for trend: p=0.004). 
5.3.1.2 Incidence and prevalence of TB 
Overall incidence of TB 
The 1,868 persons living with HIV were followed over 14,740 person years (PY), which 
corresponds to a median follow-up time of 7.9 (IQR, 3.9–11.5) years.  
Of the 92 TB cases, 48 (52%) were diagnosed within one month after HIV diagnosis (early 
TB) and 44 (48%) were diagnosed more than one month after HIV diagnosis (late TB). 
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The overall incidence rate of TB during the study period was 6.2 (95% CI 5.1–7.6) per 1,000 
PY. During the study period we observed a significant decrease in incidence of TB; this was 
equivalent to an annual rate decline of -10.1% [95% CI, -15.1-(-6.8)]. Figure 7. 
 
 
Figure 7. Incidence rate of TB in patients living with HIV in Stockholm county 1996-
2013, divided into three-year periods. The upper curve represents the incidence rate of 
TB overall. The lower curve represent the incidence within the subset of patients 
diagnosed with late TB (diagnosed >1 month after HIV diagnosis). 
The incidence of TB during the overall study period was 1.0 (95% CI 0.5-2.0) per 1,000 PY 
in patients from low TB-endemic regions and 11.3 (95% CI 9.0-14.0) per 1,000 PY in patients 
from TB-endemic regions. 
Prevalence of early TB  
We estimated the prevalence of TB at the time of HIV diagnosis under the assumption that 
patients diagnosed early with TB, i.e. within one month from their HIV diagnosis, represent 
prevalent rather than incident cases. The overall prevalence of early TB during the study 
period was 2.6% (95% CI 1.9-3.4). The prevalence of early TB increased over the study 
period: 1.6% (95% CI 0.6-3.9) during the first three years and 4.4% (95% CI 2.4-7.9) during 
the final three years (see Figure 3 in Paper III). However, the observed trend of an increasing 
prevalence of TB early at HIV diagnosis did not reach the level of statistical significance 
(p=0.064). 
Incidence of late TB  
The overall incidence of late TB was 3.0 per 1,000 PY (95% CI, 2.2–4.0). A significant 
decrease in the incidence rate of late TB was observed during the study period [-11.1% (95% 
CI, -16.9-(-5.0)]. Figure 7. 
5.3.1.3 Characteristics of TB-patients 
Of the 92 patients with HIV-TB co-infection, TB disease was culture-confirmed in 79 of the 
patients (86%). Three were diagnosed by PCR, one by sputum microscopy, five by radiography 
and three by histopathology. Resistant TB strains were detected in four patients, two had a 
multi-drug resistant strain. Active TB was diagnosed within one year from HIV diagnosis in 
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68 (73%) of the 92 co-infected patients. A TST or IGRA test was performed in ten of the 92 
patients and was positive in six. 
The characteristics of the HIV-TB co-infected patients (n=92) during the study period (grouped 
into early and late TB cases) are presented in. Table 6.  Disseminated TB and lower median 
viral load at TB diagnosis were significantly more often seen among the 44 patients with late 
TB diagnosis compared to the 48 patients with early diagnosis.  
Table 6. Characteristics of TB-patients with HIV (n=92) grouped into early and late TB. 
 All TB patients 
(n=92) 
Early TB  
(n=48) 
Late TB  
(n=44) 
Early vs Late TB 
p-value* 
CD4 at TB diagnosis, (cells/µl) median 
(IQR) 
160 (61-260) 168 (64-259) 154 (52-282) 0.759 
HIV viral load at TB diagnosis 
(cop/ml) median (IQR) 
90,100 (1,392-
550,000) 
346,000 (56,050-
813,000) 
10,295 (50-
253,250) 
0.045 
Patients diagnosed per time period, n (%)  
1996-2008  64 (69%) 31 (65%) 33 (75%) 
0.278 
2009-2013 28 (31%) 17 (35%) 11 (25%) 
Time on ART at TB diagnosis, n (%)  
No ART 64 (70%) 37 (77%) 27 (61%) 
 ≤3 months 18 (20%) 11 (23%) 7 (16%) 
>3 months 10 (10%) 0  10 (23%) 
Continent of origin, n (%)  
TB-low endemic 10 (11%) 4 (8%) 6 (14%) 
0.414 
TB-endemic 82 (89%) 44 (92%) 38 (86%) 
Clinical manifestation of TB, n (%)  
Isolated pulmonary 38 (41%) 27 (56%) 11 (25%) 
0.010 Extrapulmonary 22 (24%) 9 (19%) 13 (29%) 
Disseminated 32 (35%) 12 (25%) 20 (46%) 
Time from HIV to TB diagnosis, n (%)  
<1 months 48 (52%) 48 (100%) - 
 
1 months – 1 year 20 (22%) - 20 (46%) 
1-2 years 8 (9%) - 8 (18%) 
2-6 years 15 (16%) - 15 (34%) 
>6 years 1 (1%) - 1 (2%) 
IQR, interquartile range. *p-values refer to comparisons of the distribution of disease characteristics between 
patients with early versus late TB diagnosis. Statistically significant (p<0.05) differences in proportions of patient 
characteristics are bolded. 
In the late TB group, 32 (73%) patients were ART naïve. Seven (16%) had had effective ART 
(more than three months of treatment and a viral load <50 copies/ml at the time of TB 
diagnosis). 
5.3.1.4 Risk factors of late TB in the HIV cohort 
An increased risk for active TB more than one month from HIV diagnosis was significantly 
associated with heterosexually transmitted HIV and origin from TB-endemic continent in a 
bivariate Cox regression analysis. After adjustment in the multivariate analysis, continent of 
origin was the only characteristic that had a statistically significant association with an 
increased risk of late TB. Table 7. 
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Table 7. Results from Cox regression analysis with active TB more than one month after 
HIV diagnosis as dependent variable by characteristics at HIV diagnosis in persons 
diagnosed with HIV in Stockholm County 1996-2013 (n=1795). 
 HIV 
(n) 
TB 
(n) 
Bivariate analysis 
HR (95% CI) 
 
p-value 
Multivariate analysis 
HR (95% CI) 
 
p-value 
Total (n) 1,795 44     
Sex 
      Male 
      Female 
 
1,051 
744 
 
22 
22 
 
1.39 (0.77–2.51) 
Reference 
 
0.272* 
 
1.33 (0.70-2.51)3 
 
 
0.386 
Age (years) 
      <35 
      ≥35  
 
833 
962 
 
25 
19 
 
1.46 (0.80–2.65) 
Reference 
 
0.215* 
 
1.00 (0.54–1.86)  
 
0.999 
Route of HIV transmission 
      Heterosexual 
      Other 
 
1,155 
640 
 
35 
9 
 
2.13 (1.02-4.43) 
Reference 
 
0.043† 
 
1.04 (0.46-2.33) 
 
 
0.920 
Continent of origin 
     TB endemic 
     TB low endemic 
 
873 
922 
 
39 
5 
 
7.54 (2.97-19-13) 
Reference 
 
<0.001† 
 
8.54 (3.09-23.61) 
 
 
<0.001† 
Year of HIV diagnosis 
     1996-2008 
     2009-2013 
 
1,351 
444 
 
37 
7 
 
1.16 (0.51-2.64) 
Reference 
 
0.726* 
 
Not included 
 
CD4 at HIV diagnosis (cells/µl) 
     <200 
     ≥200 
 
536 
1,243 
 
18 
26 
 
1.67 (0.91-3.04) 
Reference 
 
0.095* 
 
Not included 
 
VL at HIV diagnosis (cop/ml) 
    <500 
    ≥500 
 
232 
1,531 
 
1 
43 
 
Reference 
6.70 (0.92-48.68) 
 
0.060* 
 
Not included 
 
 
 
 
HR, Hazard ratio; CI, confidence interval; VL, viral load. *Variables with a p-value >0.05 in bivariate analysis 
were not included in the multivariate analysis except for sex and age, which were considered to be potential 
confounding factors. †Statistically significant odds ratios (p-value < 0.05) are bolded.  
5.3.1.5 Numbers needed to treat (NNT) to prevent one case of active TB 
Based on the assumption that only the 44 patients (out of the 1795 HIV patients at risk of late 
TB) diagnosed with late TB could have had their disease prevented with LTBI treatment, and, 
anticipating that LTBI treatment would give full protection against active TB, 41 (95% CI, 31–
56) patients would have to be treated with LTBI to prevent one case of active TB (during a 
median follow-up time of 7.4 (IQR, 3.9–11.5) years). In patients originating from TB-endemic 
regions the NNT was 22 (95% CI, 15–30) (during a median follow-up time of 6.7 (IQR, 3.5–
11.1) years), also anticipating full protection by LTBI treatment.  
5.3.2 Discussion 
With the implementation of ART, we observed a significant decline in incidence rate of TB 
over time. The annual mean decrease was approximately 10%, which is in the same range as 
in most other contemporary studies from low TB incidence countries. To further reduce the 
frequency, the WHO recommends screening and treatment of LTBI in risk groups. To identify 
patients who could possibly benefit from LTBI treatment, we analyzed the association between 
certain patient characteristics at the time of HIV diagnosis and the risk of developing late TB. 
In this adjusted analysis, originating from a TB-endemic country was the only characteristic 
that was significantly associated with active TB development, a finding in congruence with 
other studies. Low CD4⁺-cell count and high HIV viral load at HIV diagnosis were also 
associated with late TB diagnosis in two contemporary studies from low-endemic settings but 
our study did not lend any support to a predictive role of these two characteristics for risk of 
developing late TB when modern ART was introduced early.  
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The majority (77%) of patients with potentially preventable TB (late TB) were ART naïve or 
had been treated with ART less than 3 months at time of TB diagnosis, which underscores the 
importance of the currently implemented strategy of introducing ART already at diagnosis in 
all patients diagnosed with HIV. Notwithstanding the probable protective effect of 
immunological reconstitution after ART, it is still worth noting that the incidence of late TB in 
our cohort at the end of the study period was roughly 80 times higher than that of the general 
population in Stockholm during the same time period according to the Public Health Agency. 
TB is still a potentially lethal infection in persons living with HIV.  
The current WHO guidelines recommend screening for and treatment of LTBI in patients 
diagnosed with HIV in low-endemic countries. This strategy is also supported by the Public 
Health Agency of Sweden. This policy is supported by a Swiss study from 2007 in which a 
significant decrease in subsequent TB incidence was shown after the implementation of a LTBI 
screening program (210). However, current WHO recommendations are being questioned in 
several European countries including Sweden. The recommendation by RAV not to screen for 
and treat LTBI in persons living with HIV is justified by the fact that Sweden has reached the 
UNAIDS 90-90-90 targets, and that all patients are required by law to attend regular monitoring 
of their HIV infection (at least twice per year) (204). The RAV statement is also grounded on 
the reported low capacity of TST and IGRA screening tests to define a population at high risk 
of developing TB. The suggested strong protective effect of early ART (and low predictive 
value of screening) gains support from a European multi-center study from 2014 which shows 
that none of the study’s 338 patients with HIV with viral suppression at the time of LTBI 
screening developed TB during the following years (211). The fear that combining ART and 
LTBI treatment (INH) would lead to more AEs could not be confirmed in a Cochrane meta-
analysis from 2015 (212). 
In our cohort we estimated that 22 people living with HIV in Sweden who had their origin 
from a TB-endemic country, had to be treated with chemoprophylaxis to prevent one case of 
late active TB. This figure is significantly higher than the estimated NNT in the formerly 
cited Swiss study, where only 8 patients (during a median follow up time of 4.4 years) with 
HIV, with an origin from endemic countries and a positive LTBI screening test had to be 
treated to prevent on active case of TB (210). However, our Swedish cohort results align with 
the estimated NNT in the recent systematic Cochrane review of TB endemic countries where 
the overall NNT for LTBI-treatment in TST positive persons living with HIV was estimated 
to 20 patients (213). Important to note is however that the estimation of NNT is very much 
dependent on length of follow-up. While most patients in the studies from endemic countries 
were followed for only a year or two, the patients in our study were followed for a median 
time of 7.4 years. The importance of follow up time for the comparison of NNT is 
highlighted by the recent British study that report a seemingly high NNT of 264  to prevent 
one case of TB annually. Had we though instead reported our results as annual NNT and as 
the British study assumed a restricted protective isoniazid effect of 60%, we would end up 
with roughly the same estimate that 271 high risk patients would need to be treated with 
chemoprophylaxis to prevent one case of active TB per year. 
In our study the majority of TB patients with active TB were diagnosed at or within 1 month 
from HIV diagnosis. The prevalence of active TB 1 month after HIV diagnosis (2.6%) in our 
cohort was significantly higher than found in a British study covering the time span 2011–2015 
(0.9%). This latter observation is in congruence with a recent Swedish study which shows that 
an increasing proportion of persons living with HIV are diagnosed late and present with 
advanced disease. It should be emphasized that preventing TB, even in the era of ART, must 
include generous HIV screening and testing routines in the community.  
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5.4 PAPER IV 
5.4.1 Results 
A total of 3,344 TB patients were registered in Stockholm County 1996–2016. Culture 
verification was obtained in 2,552 cases. Among the 2,552 culture-positive cases, 54% were 
male, 82% were of foreign origin, and 53% were originally from an area with a TB incidence 
of ≥100/100,000 population. The median age at TB diagnosis was 35 years (IQR 26-51). 
The annual numbers of culture-verified cases ranged between a minimum of 85 in 2004 to a 
maximum of 184 in 2009 (see Figure 1 in Paper IV). The median follow-up time in the study 
was 10.2 years (IQR 5.6-16.2). TB reoccurred more than 180 days after successful treatment 
completion in 60 patients. The second episode was culture-confirmed in 24/3,344 cases (0.7%). 
Out of the 24 cases with a culture-confirmed second episode the isolate could be obtained, and 
WGS analysis revealed that 12 cases were caused by relapses and five were caused by 
reinfections. Figure 8. 
 
  
Figure 8. Flow chart of culture-verified tuberculosis cases in Stockholm 1996–2016. 
In the group of 24 culture-verified recurrent cases the median age was 24 (IQR 19–38) years; 
12 (50%) were women, 20 (83%) were born abroad and 15 (62%) were originally from a region 
classified as a TB-endemic (≥100/100,000 population). The median age was significantly 
lower (p=0.04) in the group of patients with TB recurrence (see Table 1 in Paper IV). In a 
bivariate logistic regression analysis we found no significant associations between TB 
recurrence and clinical characteristics at TB diagnosis. Table 8. 
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Table 8. Results from logistic regression analysis with TB recurrence as dependent 
variable by characteristics in persons diagnosed with TB in Stockholm County 1996-2016 
(n=2,552). 
 Non TB 
recurrence 
(n= 2528) 
TB 
recurrence 
(n=24) 
Bivariate 
analysis 
OR (95% CI) 
p-
value 
Multivariate 
analysis 
OR (95% CI) 
p-value 
Age (years)           
<35   1323 17 Reference    
≥35 1205 7 2.21 (0.91–5.4) 0.08* 2.20 (0.91–5.34) 0.08 
Sex             
Female 1162 12 Reference    
Male 1366 12 1.18 (0.53–2.63) 0.52 1.16 (0.52–2.59) 0.72 
TB-incidence in country of 
origin 
      
<100/100,000  1196 9 Reference  Not included  
≥100/100,000      1332 15 1.57 (0.46–5.38) 0.47   
Clinical manifestation of TB       
Disseminated 308 5 Reference  Not included  
Pulmonary 1335 12 2.46 (0.72–8.47) 0.15   
Extrapulmonary 885 7 2.30 (0.61–8.61) 0.22   
OR, odds ratio; CI, confidence interval. Pulmonary; only lungs involved, Extrapulmonary; lungs not involved, 
Disseminated; both pulmonary and extrapulmonary involvement. *Variables with a p-value >0.10 in bivariate 
analysis were not included in the multivariate analysis except for sex, which was considered to be a potential 
confounding factor.  
In the recurrent cases (n=24) the median time between the first and the second TB episode was 
3.5 years (IQR 1.8–5.8). No case of TB recurrence was noted in patients diagnosed with their 
first TB episode 2011–2016. Figure 9.  
 
Figure 9. Year of diagnosis, first TB episode, in patients with later recurrent TB (n=24). 
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In patients analyzed with WGS (n=17) the median time between treatment completion and the 
second TB episode was 2.4 years (IQR 1.1–4.7), in relapse cases (n=12) and in reinfected cases 
(n=5) 5.4 years (IQR 3.4–11.3). Figure 10.  
 
Figure 10. Time from completion of treatment for the first TB episode to confirmation of 
the second TB episode in patients analyzed with Whole Genome Sequencing, separated 
in relapse and reinfection (n=17). 
5.4.1.1 Results of WGS 
The M.tb isolates from the 17 patients with recurrent TB underwent WGS. The Euro-American 
lineage was the most common, seen in 71% of all recurrent cases and 75% in all relapse cases. 
The number of SNPs differed from none to 1439 between the first and the second isolate. 
Although a relapse case was defined as having a maximum difference of five SNPs between 
the two isolates, for relapse case 1 (Table 9) a difference of seven SNPs was observed, but 
none of these seven SNPs were located in highly variable regions. For relapse case 3, the initial 
SNP analysis revealed a 125 SNP difference. However, further analysis showed a low 
frequency contamination with a non-mycobacterial species. When the SNP ratio cut-off was 
increased to 96%, the contamination was removed and only one SNP remained. Thus, 12 cases 
(71%) were classified as relapse and five were regarded as reinfection with a new strain, 
resulting in a relapse frequency of 0.5% for the whole study period, corresponding to an annual 
risk of 0.06% per year. Table 9. Drug resistance was present in nine (53%) of the cases with 
recurrent TB. In the 12 patients with TB relapse, six (50%) patients had a susceptible strain, 
four (33%) had an INH resistant strain and two (17%) had an MDR strain. No acquired drug 
resistance was detected in isolates of the second episode among relapse cases. Table 9. 
5.4.1.2 Risk factors for TB recurrence 
Among patients with relapse, four (36%) had adherence problems, five (46%) were smokers 
and two (18%) had alcohol or drug abuse. One patient with several risk factors for TB relapse, 
relapsed (3 SNPs difference) after 10 years. In the group of reinfected patients, all were foreign 
born and two (33%) had traveled to their country of origin the year before the second episode. 
None of the patients with TB recurrence was co-infected with HIV.  
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Table 9. Lineage and number of Single Nucleotide Polymorphisms between isolates from 
first and second TB episode. 
Case number Country of 
origin 
Number of 
Single 
Nucleotide 
Poly-
morphisms 
First episode 
Drug 
resistance 
gene 
mutation 
Whole Genome 
Sequencing 
Lineage first 
episode 
Second 
Episode 
Drug 
resistance 
gene 
mutation 
Whole Genome 
Sequencing  
Lineage second 
episode 
Relapse 1 Sweden 7 katG: nt 1-
1071 deleted 
lineage4.1.2.1 
Euro-American 
katG: nt 1-
1071 deleted 
lineage4.1.2.1 
Euro-American 
Relapse 2 Sweden 0  lineage4.1.2 
Euro-American 
 lineage4.1.2 
Euro-American 
Relapse 3 Sweden 1 (125)a  lineage4.3.3 
Euro-American 
 lineage4.3.3 
Euro-American 
Relapse 4 Afghanistan 0  lineage3.1 East-
African-Indian 
 lineage3.1 East-
African-Indian 
Relapse 5 Sweden 3  lineage4.3.3 
Euro-American 
 lineage4.3.3 
Euro- 
Reinfection 1 Peru 311 
 
katG: 
Ser315Thr 
rpoB: 
Ser450Leu 
lineage4.3.3 
Euro-American 
 lineage4.3.3 
Euro-American 
Reinfection 2 Uzbekistan 155 
 
 lineage2.2.1 
East-Asian 
 lineage2.2.1 
East-Asian 
Reinfection 3 Kenya 1317 
 
 lineage3.1 East-
African-Indian 
inhA: C-15T 
 
lineage4.6.1.2 
Euro-American 
Reinfection 4 Peru 303 
 
katG: 
Ser315Thr 
rpoB: 
Ser450Leu 
lineage4.3.3 
Euro-American 
 lineage4.3.3 
Euro-American 
Relapse 6 Somalia 1 
 
inhA: C-15T lineage4.6.1.2 
Euro-American 
inhA: C-15T lineage4.6.1.2 
Euro-American 
Relapse 7 Azerbaijan 0 katG: 
Ser315Thr 
rpoB: 
Ser450Leu 
embB: 
Gly406Asp 
pncA: 286-
InsT 
lineage2.2.1 
East-Asian 
 
 
katG: 
Ser315Thr 
rpoB: 
Ser450Leu 
embB: 
Gly406Asp 
pncA: 286-
InsT 
lineage2.2.1 
East-Asian 
Relapse 8 Somalia 4 inhA: C-15T lineage4.6.1.2 
Euro-American 
inhA:  C-15T lineage4.6.1.2 
Euro-American 
Relapse 9 Somalia 1 inhA: C-15T lineage4.6.1.2 
Euro-American 
inhA: C-15T lineage4.6.1.2 
Euro-American 
Relapse 10 Somalia 3 katG: 
Ser315Thr 
rpoB: 
Ser450Leu 
embB: 
Met306Val 
lineage4 Euro-
American 
katG: 
Ser315Thr 
rpoB: 
Ser450Leu 
embB: 
Met306Val 
lineage4 Euro-
American 
Relapse 11 Somalia 1  lineage2.2.1 
East-Asian 
 lineage2.2.1 
East-Asian 
Reinfection 5 Mongolia 1439 
 
inhA: C-15T lineage4.3.3 
Euro-American 
 lineage2.2.1 
East-Asian 
Relapse 12 Bolivia 3  lineage4 Euro-
American 
 lineage4 Euro-
American 
a This sample was contaminated with another bacterial species. If the SNP ratio cut-off was increased 
to 96%, only one SNP remained.  
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5.4.2 Discussion 
We showed that only 0.7% of the TB patients diagnosed in Stockholm County between 1996 
and 2016 had a recurrent, culture-confirmed infection during a median follow-up time of more 
than ten years. There was an indication of a somewhat higher proportion of reinfection in 
Stockholm than presented in a contemporary Finnish study. One explanation for this could be 
that the majority of TB patients in Stockholm (82%) originated from high-endemic regions, 
whereas only 14% of the patients in the Finnish cohort were of foreign origin. A higher 
prevalence of TB in some immigrant communities, in combination with socioeconomic risk 
factors such as crowded living conditions and long stays in refugee camps could be expected 
to increase the risk of reinfection. More frequent travel to TB-endemic regions among 
immigrants is probably associated with a higher risk of reinfection. Careful contact tracing is 
of utmost importance to limit the risk of new TB cases. 
M.tb has been reported to have a high genomic stability with a steady mutation rate of around 
0.3–0.5 SNPs per genome per year. With a five-SNP cut-off for the definition of relapse, the 
WGS method has been shown to better discriminate relapse from reinfection than RFLP, 
MIRU-VNTR and spoligotyping. Some cases earlier regarded as relapse, are classified as 
reinfection with WGS (157). Also, WGS has better capacity to identify minority M.tb strains 
within in populations, which may explain the previous difficulties in distinguishing relapse 
from reinfection in patients with a mixed primary infection (165). 
We observed an almost 4-fold increased frequency of resistant TB strains among patients with 
relapse and reinfection compared with the mean frequency of TB resistance reported in 
Stockholm County during the later part of our study period, although we could not accurately 
estimate the strength of the association. Our observation is in consistency with former studies 
from low endemic settings showing resistant M.tb seems to be a strong risk factors for TB 
recurrence (214). With the addition of drugs and prolonged treatment, according to the WHO 
recommendations, the outcome improves. In Sweden, patients with MDR TB are followed for 
two years after treatment completion to identify relapse at an early stage. Implementation of a 
prolonged follow-up time might be worth considering also for patients with mono drug resistant 
TB. The high frequency of resistant TB in patients with reinfection is harder to explain. 
Traveling back to regions with a high burden of resistance could be one reason. 
No case of TB recurrence was observed during the last six years of the study period. As we 
could not accurately calculate the patient time at risk, we do not know if this is a true reduction, 
but it might indicate improved TB care during recent years. 
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6 ETHICAL CONSIDERATIONS 
Not harming the study subjects and not restricting their autonomy are our most important 
ethical considerations when conducting our studies.  
Studies I, III and IV were of retrospective character and the study objects were not directly 
involved. We did not retrieve the subjects’ approval in these studies as it would likely have 
resulted in a decrease in inclusion, especially since many subjects had returned to their country 
of origin and some had died. Clinical data were retrieved from medical files and registers, and 
neither treatment nor medical care of the subjects involved could be affected in any way. All 
data were anonymized and coded before analysis and only persons directly handling the 
patients’ data had access to the code. The studies were approved by the Regional Ethical 
Review Board of Stockholm (Dnr: 2006/1445-31/, 2013/2184-32, 2015/1300-32 and 
2018/1171-31/1). 
Study II was a phase 1 trial where the study subjects received two injections with active vaccine 
or placebo. The vaccine had earlier been proved safe when administered to animals. The study 
subjects were selected according to the inclusion criteria, and were all found to be healthy at 
medical examination. They all gave written informed consent at inclusion in the study. The 
subjects were followed for AEs for 182 days. Blood samples were stored according to the 
Swedish national rules and guidelines for human biological samples (the biobank law 
2002:297). All data regarding the subjects were anonymized and coded. Only persons 
conducting the study had access the code. Data were registered in a Case Report Form and in 
patients’ files. The study was approved by the Regional Ethical Review Board of Stockholm 
(Dnr: 2007/716-31/4, 2007/1341-32). Several subjects experienced a skin reaction at the site 
of the earlier TST on the forearm. The TST was then withdrawn from the inclusion procedure 
after an amendment, approved by the Regional Ethical Review Board (Dnr: 2008/92-32). 
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7 CONCLUSIONS 
 The introduction of ART increased the success of treatment for active TB in patients 
with concomitant HIV infection. However, patients that were provided combined ART 
and TB treatment were more often burdened by adverse drug reactions than patients 
who had not yet started ART. The highest risk was observed in patients who initiated 
ART during ongoing anti-TB treatment. 
 Our study showed that the TB vaccine candidiate H4:IC31 has an acceptable safety 
profile and is immunogenic in previously BCG-vaccinated healthy individuals. Two 
vaccinations with a low dose of  H4 antigen (5-50 µg) in combination with a high dose 
of the IC31 adjuvant (500 nmol) induced the stronges T-cells response.  
 The incidence of active TB in persons living with HIV in Stockholm County declined 
significantly after the introduction of ART in 1996 but was still 80 times higher than in 
the general population at the end of the study period, 2016.  
 The frequency of relapse in patients who had completed the prescribed TB treatment 
regimen in Stockholm County was low, indicating well functioning TB care. WGS 
seems to be a useful tool to distinguish relapse from reinfection and could be used to 
improve care of TB patients and disease control measures. The high proportion of 
resistant TB strains in patients with relapsing infection indicates a need of better 
treatment control and longer follow-up time in this group.  
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8 FUTURE PERSPECTIVES 
To reduce the burden of tuberculosis worldwide it is of utmost importance to detect and treat 
patients with active TB early in their disease course. To achieve the WHO End TB Strategy 
goals, TB treatment must also be offered to persons with LTBI to prevent later development of 
active infection. However, most persons with LTBI will not develop active infection. At 
present, this means that many patients are unnecessarily exposed to months of antibiotic 
treatments associated with potentially severe side effects. Improving methods that can better 
identify persons at risk of developing active infections should be a priority. A more rapid and 
accurate diagnostic test for active TB is needed for both high- and low-endemic settings. WGS 
might in the future be an aid for an on-the-spot test, identifying mutations know to be associated 
with antibiotic resistance so that the patient can receive the correct treatment quickly. 
People living with HIV are vulnerable. Screening and treatment of LTBI in persons with HIV 
infection could be expected to substantially reduce the risk of active TB in this group, in both 
high- and low-endemic regions. Treatment regimens for LTBI based on shorter treatments with 
fewer and/or less severe side effects are under development and will probably make this 
approach more attractive even in the era of ART. Expanded HIV screening for earlier HIV 
diagnosis and early implementation of ART is also of utmost importance to further reduce the 
incidence of TB-HIV co-infection in the future. 
The increasing problem of resistant TB demands new tuberculosis vaccines that are safe, 
affordable and more effective than BCG. The promising results with the M72/AS01 vaccine, 
indicating significant protection against tuberculosis disease, are encouraging. However, future 
research will be needed on this and other vaccine candidates before they can contribute to the 
fight against the global TB epidemic.  
The patients’ integrity must always have the highest priority. To achieve collaboration with the 
patients and to overcome linguistic, cultural and socioeconomic barriers is a huge challenge – 
but it also makes the job worthwhile. 
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9 POPULÄRVETENSKAPLIG SAMMANFATTNING 
Tuberkulos (tbc) är en smittsam infektionssjukdom som under årtusenden har plågat 
mänskligheten. Sjukdomen har i alla tider framför allt drabbat fattiga och socialt utsatta 
personer. Undernäring och annan sjuklighet kan medföra att tbc-förloppet förvärras. 
Trångboddhet ökar risken för smittspridning. Med förbättrade levnadsförhållanden och med 
upptäckten av effektiv antibiotikabehandling i mitten av 1900-talet minskade förekomsten av 
tbc i drastiskt höginkomstländer. Även i Sverige var tbc tidigare en farsot men den är idag en 
ovanlig sjukdom. Ökad invandring från områden där tbc är vanligare, har dock medfört att 
sjukdomen blivit något vanligare i Sverige de senaste åren.  
Tbc orsakas av bakterien Mycobacterium tuberculosis (M.tb). Spridningen från den sjuka 
individen sker med hostningar och nysningar, så kallad luftburen smitta. När dropparna inandas 
av en annan människa och når lungorna försöker immunförsvaret döda bakterierna. Bakterien 
har utvecklat ett försvar mot dessa attacker och lyckas ofta överleva i kroppen i en inaktiv form, 
så kallad latent tbc. Personer med latent tbc är varken sjuka eller smittsamma. Senare i livet, 
oftast inom några år efter smittotillfället, kan bakterierna ”vakna” och orsaka aktiv och 
smittsam sjukdom. Detta drabbar ungefär 10 % av de i övrigt friska personer som smittats med 
tbc-bakterien.  
M.tb har flera egenskaper som gör att den är svår att avdöda. Vid aktiv tbc behandlas patienten 
med ett flertal antibiotika under minst sex månader. Personer som är bärare av latent tbc 
behandlas oftast med ett eller två läkemedel under tre till nio månader. Tbc-läkemedel kan 
orsaka biverkningar. Leverpåverkan är den mest allvarliga biverkan men behandlade personer 
kan även drabbas av svåra besvär från, nervsystemet, mag-tarm-kanalen, leder och hud. Dessa 
faktorer gör det ibland svårt för patienten att följa behandlings-ordinationerna. 
Vid infektion med humant immunbristvirus (hiv) försvagas den del av immunförsvaret (CD4⁺ 
celler) som är viktigast i skyddet mot tbc. Hiv smittade personer löper därför en ökad risk för 
att insjukna i aktiv tbc. Hiv började spridas över världen under 1980-talet vilket ledde till att 
även förekomsten av och dödligheten i tbc ökade under efterföljande decennier. Värst drabbat 
är Afrika söder om Sahara. Antiretroviral behandling (ART), som effektivt hämmar virusets 
förmåga att föröka sig, infördes i den rika delen av världen på 1990-talet. Hiv är numer en 
behandlingsbar om än ännu inte botbar sjukdom men ART är fortfarande inte tillgängligt för 
alla hiv-drabbade personer i världen. Risken för att drabbas av biverkningar av tbc-
behandlingen är större för personer med HIV som samtidigt behandlas med ART. 
Trots att botande behandling mot tbc finns sedan 1960-talet så är sjukdomen fortfarande en av 
de vanligaste dödsorsakerna i världen. Världshälsoorganisationen (WHO) rapporterade 2017, 
10 millioner nya fall av tbc och 1,6 millioner dödsfall. Av de döda var 300 000 även infekterade 
med hiv. Ökad förekomst av resistent tbc det senaste decenniet har försvårat världssamfundets 
möjligheter att begränsa sjukdomens spridning. Trots dessa utmaningar formulerade WHO 
2014 målsättningen att minska förekomsten av tbc med 90 % år 2035. För att uppnå målet 
måste tbc-epidemin angripas på flera olika sätt.  
 Ett förbättrat vaccin mot tbc skulle vara ett oerhört viktigt redskap i den globala kampen 
mot sjukdomen. Det sedan länge använda tbc-vaccinet Bacille-Calmette Guerain 
(BCG) ger visserligen ett gott skydd mot tbc hos barn under fem år men har otillräcklig 
effekt hos vuxna.  
 Kortare behandlingstider med mindre biverkningsframkallande läkemedel skulle leda 
till färre behandlingsavbrott och därmed förbättrade behandlingsresultat bland patienter 
med både latent och aktiv tbc vilket också skulle leda till kraftig minskning av 
spridningen av infektionen. 
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 De flesta personer som bär på Mtb kommer inte att utveckla aktiv sjukdom. Förbättrade 
diagnostiska metoder som kan avgränsa de personer med latent tbc som löper särskilt 
stor risk för att utveckla aktiv tbc skulle kunna bespara många individer och samhället 
verkningslös, biverkningsbehäftad och resistensdrivande antibiotikabehandling.  
Studier i låginkomstländer har visat att strukturerade insatser för att upptäcka och behandla 
personer med latent tbc leder till kraftig minskning av insjuknande i aktiv tbc och då framför 
allt hos personer med samtidig hiv-infektion. WHO rekommenderar därför screening och 
behandling av latent tbc hos alla personer som lever med hiv. Den svenska 
Folkhälsomyndigheten rekommenderar i första hand behandling av latent tbc hos hiv smittade 
personer som ännu inte har påbörjat ART. Sverige har förhållandevis låg förekomst av hiv men 
migranter från vissa områden i världen är mer drabbade. Hiv-vården i Sverige är mycket 
välfungerande. Den svenska Referensgruppen för AntiViral terapi (RAV) gjorde 2017 
uppskattningen att mer än 90 % av alla de som levde med infektionen hade effektiv ART-
behandling och välfungerande immunförsvar (normala CD4⁺ cell). RAV har därför beslutat om 
att inte rekommendera behandling av latent tbc då de anser att den förmodligen gör mer skada 
än nytta.  
Syftet med denna avhandling var att öka kunskapen om tbc, med betoning på förebyggande 
behandling, i ett lågendemiskt område med ökande migration från högendemiska länder. 
I den första studien beskrevs förekomsten av tbc och de biverkningar som uppstod under tbc-
behandlingen hos personer med som lever med hiv i Stockholms län sedan hiv-epidemins 
början. I studien, som spänner över 1987 till 2013 fann vi att förekomsten av tbc var högst 
bland migranter från endemiskt tbc-område och att förekomsten minskade betydligt efter 
införandet av ART 1996. Personer som startade behandling med ART under pågående tbc-
behandling och personer med dåligt immunförsvar (låga CD4⁺ celler) fick mest biverkningar. 
De vanligaste biverkningarna var leverpåverkan och neurologiska symptom.  
I den andra studien undersökte vi om ett nytt tbc-vaccin var säkert för människor och gav 
upphov till önskvärd reaktion från immunförsvaret. Tidigare BCG-vaccinerade 
försökspersonerna lottades till att få aktivt vaccin eller placebo och följdes avseende 
biverkningar. För att undersöka reaktionsmönstret i immunförsvaret togs blodprover. Vi kunde 
visa att vaccinet inte orsakade fler allvarliga biverkningar än placebo och att en reaktivitet hos 
immunförsvaret kvarstod ännu ett halvår efter den sista injektionen med aktivt vaccin. Även 
om dessa resultat är lovande så måste, för att uttala sig om vaccinets eventuella skyddseffekt, 
vaccinet prövas på ett stort antal människor i ett tbc-endemiskt område. Personerna måste sedan 
följas under flera år. 
I den tredje studien ville vi titta på behovet av behandling av latent tbc hos personer som lever 
med hiv i Stockholm sedan införandet av ART 1996 till 2016. Vi fann att tbc var 80 gånger 
vanligare bland personer med HIV, med ursprung från tbc-endemiskt område, jämfört med 
normalbefolkningen. Bland de patienter som insjuknade i tbc, hade merparten (77 %) inte 
effektiv ART. Utifrån studieobservationerna kunde vi beräkna att ungefär 22 patienter, bland 
de med ursprung från ett tbc-endemiskt område, behöver behandlas för latent tbc för att ett fall 
av aktiv tbc skall kunna undvikas. Studien besvarar inte frågan om personer med hiv-infektion 
som bär på tbc i ett lågendemiskt land verkligen bör behandlas med långa antibiotikakurer mot 
tbc men studien tillhandahåller ett konkret underlag för det fortsatta arbetet med att väga nyttan 
mot risken med sådan behandling så att vården kan utformas på bästa sätt för både tbc smittade 
individer och för samhället.  
I den fjärde studien ville vi, genom undersökning av arvsmassan hos tbc-bakterien, så kallad 
helgenomsekvensering (WGS), se om personer som återföll i tbc efter slutförd behandling i 
Stockholms län 1996-2016, återinsjuknade med samma stam eller om de var nyinfekterade 
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med en annan stam. Vi kunde visa att endast 0,7 % av alla personer som drabbats av aktiv tbc 
kom att återfalla i infektionen under de följande 10 åren och att återinsjuknande med samma 
stam var vanligast. De flesta som återföll var infekterade med en resistent tbc-stam. Resultatet 
tyder på att tbc-vården fungerar väl men att uppföljningstiden för personer med resistent tbc 
kan behöva förlängas så att de som ändå återinsjuknar upptäcks i tid.    
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